OA19779A - Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation. - Google Patents
Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation. Download PDFInfo
- Publication number
- OA19779A OA19779A OA1201700204 OA19779A OA 19779 A OA19779 A OA 19779A OA 1201700204 OA1201700204 OA 1201700204 OA 19779 A OA19779 A OA 19779A
- Authority
- OA
- OAPI
- Prior art keywords
- group
- pyridin
- mmol
- mixture
- alkyl
- Prior art date
Links
- 230000001965 increased Effects 0.000 title abstract description 10
- 150000003935 benzaldehydes Chemical class 0.000 title abstract description 8
- 230000000287 tissue oxygenation Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims description 144
- FWCVZAQENIZVMY-UHFFFAOYSA-N 2-hydroxy-6-[[2-(2-propan-2-ylpyrazol-3-yl)pyridin-3-yl]methoxy]benzaldehyde Chemical compound CC(C)N1N=CC=C1C1=NC=CC=C1COC1=CC=CC(O)=C1C=O FWCVZAQENIZVMY-UHFFFAOYSA-N 0.000 claims description 13
- 239000000546 pharmaceutic aid Substances 0.000 claims description 6
- 208000007056 Sickle Cell Anemia Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims 1
- HUMNYLRZRPPJDN-UHFFFAOYSA-N Benzaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 abstract description 44
- 230000000051 modifying Effects 0.000 abstract description 33
- 108010054147 Hemoglobins Proteins 0.000 abstract description 30
- 102000001554 Hemoglobins Human genes 0.000 abstract description 30
- 230000003281 allosteric Effects 0.000 abstract description 18
- 201000010099 disease Diseases 0.000 abstract description 18
- 239000000543 intermediate Substances 0.000 abstract description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 135
- 239000000203 mixture Substances 0.000 description 133
- -1 protons Chemical compound 0.000 description 87
- 235000019439 ethyl acetate Nutrition 0.000 description 64
- 239000000243 solution Substances 0.000 description 61
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 56
- 125000005843 halogen group Chemical group 0.000 description 48
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 47
- 239000007787 solid Substances 0.000 description 46
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 44
- 229910052760 oxygen Inorganic materials 0.000 description 43
- 125000001072 heteroaryl group Chemical group 0.000 description 42
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- 125000000217 alkyl group Chemical group 0.000 description 30
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 30
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 30
- 108010016797 Sickle Hemoglobin Proteins 0.000 description 29
- 239000001301 oxygen Substances 0.000 description 28
- 239000000741 silica gel Substances 0.000 description 28
- 229910002027 silica gel Inorganic materials 0.000 description 28
- 239000003480 eluent Substances 0.000 description 27
- 229910052739 hydrogen Inorganic materials 0.000 description 27
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 26
- 239000012044 organic layer Substances 0.000 description 25
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 24
- 239000008079 hexane Substances 0.000 description 24
- 239000011541 reaction mixture Substances 0.000 description 24
- 229940095076 benzaldehyde Drugs 0.000 description 22
- 229910002092 carbon dioxide Inorganic materials 0.000 description 22
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 21
- 125000004429 atoms Chemical group 0.000 description 21
- 239000001257 hydrogen Substances 0.000 description 20
- 125000006239 protecting group Chemical group 0.000 description 20
- 239000011780 sodium chloride Substances 0.000 description 20
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 125000004432 carbon atoms Chemical group C* 0.000 description 17
- 125000004043 oxo group Chemical group O=* 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 16
- 125000001424 substituent group Chemical group 0.000 description 16
- 239000007832 Na2SO4 Substances 0.000 description 15
- 239000010410 layer Substances 0.000 description 15
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 15
- 229910000027 potassium carbonate Inorganic materials 0.000 description 15
- 238000000746 purification Methods 0.000 description 15
- 150000003839 salts Chemical class 0.000 description 15
- 229910052938 sodium sulfate Inorganic materials 0.000 description 15
- 210000004369 Blood Anatomy 0.000 description 14
- 238000007792 addition Methods 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 150000002431 hydrogen Chemical class 0.000 description 13
- 229910052702 rhenium Inorganic materials 0.000 description 13
- HWNIBJPEJAWOTR-UHFFFAOYSA-N 5-hydroxy-2-methoxybenzaldehyde Chemical compound COC1=CC=C(O)C=C1C=O HWNIBJPEJAWOTR-UHFFFAOYSA-N 0.000 description 12
- 125000003342 alkenyl group Chemical group 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 11
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 11
- 125000000304 alkynyl group Chemical group 0.000 description 11
- 238000004166 bioassay Methods 0.000 description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 11
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 10
- 125000003118 aryl group Chemical group 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 125000000753 cycloalkyl group Chemical group 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 235000015320 potassium carbonate Nutrition 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 239000012230 colorless oil Substances 0.000 description 9
- 125000005842 heteroatoms Chemical group 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 229940002612 prodrugs Drugs 0.000 description 8
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Chemical compound [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 229910052717 sulfur Inorganic materials 0.000 description 8
- JFDZBHWFFUWGJE-UHFFFAOYSA-N Benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 210000004027 cells Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229940093499 ethyl acetate Drugs 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- SRJOCJYGOFTFLH-UHFFFAOYSA-M piperidine-4-carboxylate Chemical compound [O-]C(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-M 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000001225 therapeutic Effects 0.000 description 6
- 210000001519 tissues Anatomy 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- GTAYSDREQLXNMN-UHFFFAOYSA-N 2-fluoro-6-[[2-(2-propan-2-ylpyrazol-3-yl)pyridin-3-yl]methoxy]benzaldehyde Chemical compound CC(C)N1N=CC=C1C1=NC=CC=C1COC1=CC=CC(F)=C1C=O GTAYSDREQLXNMN-UHFFFAOYSA-N 0.000 description 5
- LLNUXVXQOAESCE-UHFFFAOYSA-N 2-fluoro-6-[[2-[2-(3,3,3-trifluoropropyl)pyrazol-3-yl]pyridin-3-yl]methoxy]benzaldehyde Chemical compound FC1=CC=CC(OCC=2C(=NC=CC=2)C=2N(N=CC=2)CCC(F)(F)F)=C1C=O LLNUXVXQOAESCE-UHFFFAOYSA-N 0.000 description 5
- GLOMHHFHVMYMMP-UHFFFAOYSA-N 2-hydroxy-6-[[3-(2H-tetrazol-5-yl)phenyl]methoxy]benzaldehyde Chemical compound OC1=CC=CC(OCC=2C=C(C=CC=2)C2=NNN=N2)=C1C=O GLOMHHFHVMYMMP-UHFFFAOYSA-N 0.000 description 5
- FMISYJFGLRUTEK-UHFFFAOYSA-N 2-methoxy-5-[[2-(2-propan-2-ylpyrazol-3-yl)pyridin-3-yl]methoxy]benzaldehyde Chemical compound C1=C(C=O)C(OC)=CC=C1OCC1=CC=CN=C1C1=CC=NN1C(C)C FMISYJFGLRUTEK-UHFFFAOYSA-N 0.000 description 5
- HAMHSPLHZAFUHD-UHFFFAOYSA-N 4-[(2-formylphenoxy)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1COC1=CC=CC=C1C=O HAMHSPLHZAFUHD-UHFFFAOYSA-N 0.000 description 5
- QHYINIBXOSBMIT-UHFFFAOYSA-N 5-methoxy-2-(quinolin-5-ylmethoxy)benzaldehyde Chemical compound O=CC1=CC(OC)=CC=C1OCC1=CC=CC2=NC=CC=C12 QHYINIBXOSBMIT-UHFFFAOYSA-N 0.000 description 5
- 239000004215 Carbon black (E152) Substances 0.000 description 5
- 210000003743 Erythrocytes Anatomy 0.000 description 5
- BQJCRHHNABKAKU-KBQPJGBKSA-N Morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 5
- 210000002381 Plasma Anatomy 0.000 description 5
- 210000003324 RBC Anatomy 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 5
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 description 5
- KCSCDCNKTFHIKY-UHFFFAOYSA-N methyl 3-[(2-formylphenoxy)methyl]benzoate Chemical compound COC(=O)C1=CC=CC(COC=2C(=CC=CC=2)C=O)=C1 KCSCDCNKTFHIKY-UHFFFAOYSA-N 0.000 description 5
- USZUSRQZXDALNJ-UHFFFAOYSA-N methyl 4-[(2-formylphenoxy)methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1COC1=CC=CC=C1C=O USZUSRQZXDALNJ-UHFFFAOYSA-N 0.000 description 5
- 230000003000 nontoxic Effects 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 238000006116 polymerization reaction Methods 0.000 description 5
- 125000003226 pyrazolyl group Chemical group 0.000 description 5
- 230000002194 synthesizing Effects 0.000 description 5
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- SXAGDDZDKOILKR-UHFFFAOYSA-N 1-methoxy-4-(methoxymethoxy)benzene Chemical compound COCOC1=CC=C(OC)C=C1 SXAGDDZDKOILKR-UHFFFAOYSA-N 0.000 description 4
- DGXAGETVRDOQFP-UHFFFAOYSA-N 2,6-dihydroxybenzaldehyde Chemical compound OC1=CC=CC(O)=C1C=O DGXAGETVRDOQFP-UHFFFAOYSA-N 0.000 description 4
- OYRNMRHRANZAEA-UHFFFAOYSA-N 2-(1H-indazol-4-ylmethoxy)-5-methoxybenzaldehyde Chemical compound O=CC1=CC(OC)=CC=C1OCC1=CC=CC2=C1C=NN2 OYRNMRHRANZAEA-UHFFFAOYSA-N 0.000 description 4
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- SRJOCJYGOFTFLH-UHFFFAOYSA-N Isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 4
- 150000001336 alkenes Chemical class 0.000 description 4
- 125000004350 aryl cycloalkyl group Chemical group 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 150000004292 cyclic ethers Chemical class 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 125000004438 haloalkoxy group Chemical group 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminum hydride Chemical compound [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- XOHUEYCVLUUEJJ-UHFFFAOYSA-N 2,3-DPG Chemical compound OP(=O)(O)OC(C(=O)O)COP(O)(O)=O XOHUEYCVLUUEJJ-UHFFFAOYSA-N 0.000 description 3
- WZUODJNEIXSNEU-UHFFFAOYSA-N 2-Hydroxy-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C(O)=C1 WZUODJNEIXSNEU-UHFFFAOYSA-N 0.000 description 3
- FZHSPPYCNDYIKD-UHFFFAOYSA-N 2-Hydroxy-5-methoxybenzaldehyde Chemical compound COC1=CC=C(O)C(C=O)=C1 FZHSPPYCNDYIKD-UHFFFAOYSA-N 0.000 description 3
- JODZFLKUSXUCLB-UHFFFAOYSA-N 2-methoxy-5-(methoxymethoxy)benzaldehyde Chemical compound COCOC1=CC=C(OC)C(C=O)=C1 JODZFLKUSXUCLB-UHFFFAOYSA-N 0.000 description 3
- PHGADRUHZNQNFN-UHFFFAOYSA-N 5-methoxy-2-[(1-methylindazol-4-yl)methoxy]benzaldehyde Chemical compound O=CC1=CC(OC)=CC=C1OCC1=CC=CC2=C1C=NN2C PHGADRUHZNQNFN-UHFFFAOYSA-N 0.000 description 3
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- OGYGFUAIIOPWQD-UHFFFAOYSA-N Thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 238000006392 deoxygenation reaction Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- OCZDCIYGECBNKL-UHFFFAOYSA-N lithium;alumanuide Chemical compound [Li+].[AlH4-] OCZDCIYGECBNKL-UHFFFAOYSA-N 0.000 description 3
- 230000001404 mediated Effects 0.000 description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 3
- 230000001264 neutralization Effects 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000004497 pyrazol-5-yl group Chemical group N1N=CC=C1* 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 230000002829 reduced Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000001984 thiazolidinyl group Chemical group 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- QIQZUABMLGJKJP-UHFFFAOYSA-N (2-bromopyridin-3-yl)methanol Chemical compound OCC1=CC=CN=C1Br QIQZUABMLGJKJP-UHFFFAOYSA-N 0.000 description 2
- UYZJZYVCRVEGDE-UHFFFAOYSA-N (2-bromopyridin-3-yl)methoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCC1=CC=CN=C1Br UYZJZYVCRVEGDE-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-FIBGUPNXSA-N 2,2,2-trideuterioacetonitrile Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 2
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 2
- WVHJZEYCVGEZHM-UHFFFAOYSA-N 2-bromo-3-[[2-(2-propan-2-ylpyrazol-3-yl)pyridin-3-yl]methoxy]benzaldehyde Chemical compound CC(C)N1N=CC=C1C1=NC=CC=C1COC1=CC=CC(C=O)=C1Br WVHJZEYCVGEZHM-UHFFFAOYSA-N 0.000 description 2
- FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 description 2
- BUSDPAIYNWOKOG-UHFFFAOYSA-N 2-hydroxy-6-[[2-[2-(2,2,2-trifluoroethyl)pyrazol-3-yl]pyridin-3-yl]methoxy]benzaldehyde Chemical compound OC1=CC=CC(OCC=2C(=NC=CC=2)C=2N(N=CC=2)CC(F)(F)F)=C1C=O BUSDPAIYNWOKOG-UHFFFAOYSA-N 0.000 description 2
- VPPVYRNEOIHMAM-UHFFFAOYSA-N 2-hydroxy-6-[[2-[2-(3,3,3-trifluoropropyl)pyrazol-3-yl]pyridin-3-yl]methoxy]benzaldehyde Chemical compound OC1=CC=CC(OCC=2C(=NC=CC=2)C=2N(N=CC=2)CCC(F)(F)F)=C1C=O VPPVYRNEOIHMAM-UHFFFAOYSA-N 0.000 description 2
- GHVNNICPZOBPSX-UHFFFAOYSA-N 2-hydroxy-6-[[4-(2H-tetrazol-5-yl)phenyl]methoxy]benzaldehyde Chemical compound OC1=CC=CC(OCC=2C=CC(=CC=2)C=2NN=NN=2)=C1C=O GHVNNICPZOBPSX-UHFFFAOYSA-N 0.000 description 2
- NYHLBAMZRLASKV-UHFFFAOYSA-N 3,3,3-trifluoropropylhydrazine;dihydrochloride Chemical compound Cl.Cl.NNCCC(F)(F)F NYHLBAMZRLASKV-UHFFFAOYSA-N 0.000 description 2
- GVVRAUQIPLTEHK-UHFFFAOYSA-N 3-[[tert-butyl(dimethyl)silyl]oxymethyl]pyridine-2-carbonitrile Chemical compound CC(C)(C)[Si](C)(C)OCC1=CC=CN=C1C#N GVVRAUQIPLTEHK-UHFFFAOYSA-N 0.000 description 2
- URVBYANBZXJPEM-UHFFFAOYSA-N 3-bromo-2-(hydroxymethyl)phenol Chemical compound OCC1=C(O)C=CC=C1Br URVBYANBZXJPEM-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- KRGGDHHVSYRSIR-UHFFFAOYSA-N 5-methoxy-2-(1H-pyrrolo[2,3-b]pyridin-4-ylmethoxy)benzaldehyde Chemical compound O=CC1=CC(OC)=CC=C1OCC1=CC=NC2=C1C=CN2 KRGGDHHVSYRSIR-UHFFFAOYSA-N 0.000 description 2
- GXQNKVDAAINMNE-UHFFFAOYSA-N 5-methoxy-2-(pyridin-3-ylmethoxy)benzaldehyde Chemical compound O=CC1=CC(OC)=CC=C1OCC1=CC=CN=C1 GXQNKVDAAINMNE-UHFFFAOYSA-N 0.000 description 2
- 230000037082 AUClast Effects 0.000 description 2
- ORWKVZNEPHTCQE-UHFFFAOYSA-N Acetic formic anhydride Chemical compound CC(=O)OC=O ORWKVZNEPHTCQE-UHFFFAOYSA-N 0.000 description 2
- 229920002799 BoPET Polymers 0.000 description 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N Chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 229960002433 Cysteine Drugs 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- UAOMVDZJSHZZME-UHFFFAOYSA-N Diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 2
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methane sulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 2
- 108010085682 Hemoglobin A Proteins 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N Hypoxanthine Chemical group O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 239000004201 L-cysteine Substances 0.000 description 2
- 235000013878 L-cysteine Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N Manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N Meta-Chloroperoxybenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- 239000005041 Mylar™ Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 208000008425 Protein Deficiency Diseases 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 150000004753 Schiff bases Chemical class 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N Theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Trimethylglycine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- LEIMLDGFXIOXMT-UHFFFAOYSA-N Trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Chemical group O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 125000005872 benzooxazolyl group Chemical group 0.000 description 2
- OOHLKKPFDOIXAK-UHFFFAOYSA-N benzyl N-(3,3,3-trifluoropropylamino)carbamate Chemical compound FC(F)(F)CCNNC(=O)OCC1=CC=CC=C1 OOHLKKPFDOIXAK-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- AOGYCOYQMAVAFD-UHFFFAOYSA-M carbonochloridate Chemical compound [O-]C(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-M 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 230000001808 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- VTWRFRVMKPWCFL-UHFFFAOYSA-N diethyl phosphite Chemical compound CCOP([O-])OCC VTWRFRVMKPWCFL-UHFFFAOYSA-N 0.000 description 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- TUCNEACPLKLKNU-UHFFFAOYSA-N ethanone Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 2
- HPFQJBOXPBNOJK-UHFFFAOYSA-N ethyl 1-oxidopyridin-1-ium-3-carboxylate Chemical compound CCOC(=O)C1=CC=C[N+]([O-])=C1 HPFQJBOXPBNOJK-UHFFFAOYSA-N 0.000 description 2
- MFXGPGNNLRCMNW-UHFFFAOYSA-N ethyl 2-(aminomethyl)pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=CN=C1CN MFXGPGNNLRCMNW-UHFFFAOYSA-N 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 125000000262 haloalkenyl group Chemical group 0.000 description 2
- 125000000232 haloalkynyl group Chemical group 0.000 description 2
- 150000002373 hemiacetals Chemical class 0.000 description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- LIAWOTKNAVAKCX-UHFFFAOYSA-N hydrazine;dihydrochloride Chemical compound Cl.Cl.NN LIAWOTKNAVAKCX-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical group Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 230000001146 hypoxic Effects 0.000 description 2
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000000116 mitigating Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000000369 oxido group Chemical group [*]=O 0.000 description 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 2
- 125000004430 oxygen atoms Chemical group O* 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 125000004434 sulfur atoms Chemical group 0.000 description 2
- MTXGYOUJHZKFDT-UHFFFAOYSA-N tert-butyl 4-(chloromethyl)indazole-1-carboxylate Chemical compound C1=CC=C2N(C(=O)OC(C)(C)C)N=CC2=C1CCl MTXGYOUJHZKFDT-UHFFFAOYSA-N 0.000 description 2
- QSEREUCHYJATAH-UHFFFAOYSA-N tert-butyl 4-[(2-formyl-4-methoxyphenoxy)methyl]indazole-1-carboxylate Chemical compound O=CC1=CC(OC)=CC=C1OCC1=CC=CC2=C1C=NN2C(=O)OC(C)(C)C QSEREUCHYJATAH-UHFFFAOYSA-N 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 230000002588 toxic Effects 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- LYPYZKKPXUWCKT-UHFFFAOYSA-N (1-methylindazol-4-yl)methanol Chemical compound C1=CC=C2N(C)N=CC2=C1CO LYPYZKKPXUWCKT-UHFFFAOYSA-N 0.000 description 1
- XOHUEYCVLUUEJJ-UWTATZPHSA-N (2R)-2,3-bis(phosphonooxy)propanoic acid Chemical compound OP(=O)(O)O[C@@H](C(=O)O)COP(O)(O)=O XOHUEYCVLUUEJJ-UWTATZPHSA-N 0.000 description 1
- GEMCNTAYIYTBJF-ZRDIBKRKSA-N (E)-1-[3-[[tert-butyl(dimethyl)silyl]oxymethyl]pyridin-2-yl]-3-(dimethylamino)prop-2-en-1-one Chemical compound CN(C)\C=C\C(=O)C1=NC=CC=C1CO[Si](C)(C)C(C)(C)C GEMCNTAYIYTBJF-ZRDIBKRKSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- BPZAIOKOQDGVMQ-UHFFFAOYSA-N 1-(1,3-thiazolidin-3-yl)ethanone Chemical group CC(=O)N1CCSC1 BPZAIOKOQDGVMQ-UHFFFAOYSA-N 0.000 description 1
- BYLAWYTWAYOBDP-UHFFFAOYSA-N 1-chlorobutane Chemical group [CH2]CCCCl BYLAWYTWAYOBDP-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- BVRPEWYZJJACMM-UHFFFAOYSA-N 1-oxidopiperazin-1-ium Chemical compound [O-][NH+]1CCNCC1 BVRPEWYZJJACMM-UHFFFAOYSA-N 0.000 description 1
- QWRROAJLERSNJU-UHFFFAOYSA-N 1H-imidazo[4,5-b]pyridine;methanol Chemical compound OC.C1=CC=C2NC=NC2=N1 QWRROAJLERSNJU-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-Dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 1
- UKIYIINGHXJEDG-UHFFFAOYSA-N 2-(imidazo[1,2-a]pyridin-2-ylmethoxy)-5-methoxybenzaldehyde Chemical compound O=CC1=CC(OC)=CC=C1OCC1=CN(C=CC=C2)C2=N1 UKIYIINGHXJEDG-UHFFFAOYSA-N 0.000 description 1
- FKALBRNKMNOVHC-UHFFFAOYSA-N 2-(imidazo[1,5-a]pyridin-6-ylmethoxy)-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C(OCC2=CN3C=NC=C3C=C2)=C1 FKALBRNKMNOVHC-UHFFFAOYSA-N 0.000 description 1
- HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical class O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N 2-Imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- HHLJUSLZGFYWKW-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol;hydron;chloride Chemical compound Cl.OCCN(CCO)CCO HHLJUSLZGFYWKW-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- LQTXMBDCLHZDAM-UHFFFAOYSA-N 2-bromo-6-hydroxybenzaldehyde Chemical compound OC1=CC=CC(Br)=C1C=O LQTXMBDCLHZDAM-UHFFFAOYSA-N 0.000 description 1
- MMWNKXIFVYQOTK-UHFFFAOYSA-N 2-bromopyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1Br MMWNKXIFVYQOTK-UHFFFAOYSA-N 0.000 description 1
- QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 1
- ULQQGOGMQRGFFR-UHFFFAOYSA-N 2-chlorobenzenecarboperoxoic acid Chemical compound OOC(=O)C1=CC=CC=C1Cl ULQQGOGMQRGFFR-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- QZQXJMNHOPSYBC-UHFFFAOYSA-N 2-fluoro-6-[[2-[2-(2,2,2-trifluoroethyl)pyrazol-3-yl]pyridin-3-yl]methoxy]benzaldehyde Chemical compound FC1=CC=CC(OCC=2C(=NC=CC=2)C=2N(N=CC=2)CC(F)(F)F)=C1C=O QZQXJMNHOPSYBC-UHFFFAOYSA-N 0.000 description 1
- DYNFCHNNOHNJFG-UHFFFAOYSA-N 2-formylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1C=O DYNFCHNNOHNJFG-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- BRCHAURZFWYZOW-UHFFFAOYSA-N 2-methoxy-5-[[2-(2H-tetrazol-5-yl)pyridin-3-yl]methoxy]benzaldehyde Chemical compound C1=C(C=O)C(OC)=CC=C1OCC1=CC=CN=C1C1=NNN=N1 BRCHAURZFWYZOW-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- UKTHRMMETXCGBZ-UHFFFAOYSA-N 3-(chloromethyl)-2-(2-propan-2-ylpyrazol-3-yl)pyridine;hydrochloride Chemical compound Cl.CC(C)N1N=CC=C1C1=NC=CC=C1CCl UKTHRMMETXCGBZ-UHFFFAOYSA-N 0.000 description 1
- ZICBELWWZGYPGE-UHFFFAOYSA-N 3-(chloromethyl)-2-[2-(2,2,2-trifluoroethyl)pyrazol-3-yl]pyridine;hydrochloride Chemical compound Cl.FC(F)(F)CN1N=CC=C1C1=NC=CC=C1CCl ZICBELWWZGYPGE-UHFFFAOYSA-N 0.000 description 1
- SAUGMJLWYLQPEM-UHFFFAOYSA-N 3-bromo-1,1,1-trifluoropropane Chemical compound FC(F)(F)CCBr SAUGMJLWYLQPEM-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 1
- YWXHEIMWLKXGQI-UHFFFAOYSA-N 4-(chloromethyl)-1H-indazole Chemical compound ClCC1=CC=CC2=C1C=NN2 YWXHEIMWLKXGQI-UHFFFAOYSA-N 0.000 description 1
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
- XEDONBRPTABQFB-UHFFFAOYSA-N 4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1COC1=CC=CC(O)=C1C=O XEDONBRPTABQFB-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- BJRVCVXCUZTNOT-UHFFFAOYSA-N 4-fluoro-2-(imidazo[1,2-a]pyridin-8-ylmethoxy)benzaldehyde Chemical compound FC1=CC=C(C=O)C(OCC=2C3=NC=CN3C=CC=2)=C1 BJRVCVXCUZTNOT-UHFFFAOYSA-N 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- SLOGXPFGRINSDA-UHFFFAOYSA-N 5-[(2-bromopyridin-3-yl)methoxy]-2-methoxybenzaldehyde Chemical compound C1=C(C=O)C(OC)=CC=C1OCC1=CC=CN=C1Br SLOGXPFGRINSDA-UHFFFAOYSA-N 0.000 description 1
- YNTCMABHIDTLLK-UHFFFAOYSA-N 5-[(4-formyl-6-methoxypyridin-3-yl)oxymethyl]pyridine-3-carboxylic acid Chemical compound C1=NC(OC)=CC(C=O)=C1OCC1=CN=CC(C(O)=O)=C1 YNTCMABHIDTLLK-UHFFFAOYSA-N 0.000 description 1
- OAKLOYATUAFQQI-UHFFFAOYSA-N 5-methoxy-2-(1H-pyrazolo[3,4-b]pyridin-4-ylmethoxy)benzaldehyde Chemical compound O=CC1=CC(OC)=CC=C1OCC1=CC=NC2=C1C=NN2 OAKLOYATUAFQQI-UHFFFAOYSA-N 0.000 description 1
- ZGAQYTGICSHQIN-UHFFFAOYSA-N 5-methoxy-2-(pyrazolo[1,5-a]pyrazin-3-ylmethoxy)benzaldehyde Chemical compound O=CC1=CC(OC)=CC=C1OCC1=C2C=NC=CN2N=C1 ZGAQYTGICSHQIN-UHFFFAOYSA-N 0.000 description 1
- NRGBAMJCLLKMCZ-UHFFFAOYSA-N 5-methoxy-2-(pyrrolo[1,2-a]pyrazin-4-ylmethoxy)benzaldehyde Chemical compound O=CC1=CC(OC)=CC=C1OCC1=CN=CC2=CC=CN12 NRGBAMJCLLKMCZ-UHFFFAOYSA-N 0.000 description 1
- QSJNCVCFMKNDKW-UHFFFAOYSA-N 5-methoxy-2-[(8-methylimidazo[1,2-a]pyridin-2-yl)methoxy]benzaldehyde Chemical compound O=CC1=CC(OC)=CC=C1OCC1=CN(C=CC=C2C)C2=N1 QSJNCVCFMKNDKW-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- CWDLNRKREBPISR-UHFFFAOYSA-N 6-[(2-formyl-4-methoxyphenoxy)methyl]pyrrolo[1,2-a]pyrazine-7-carboxamide Chemical compound O=CC1=CC(OC)=CC=C1OCC1=C(C(N)=O)C=C2N1C=CN=C2 CWDLNRKREBPISR-UHFFFAOYSA-N 0.000 description 1
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 1
- 241000349731 Afzelia bipindensis Species 0.000 description 1
- 208000008445 Altitude Sickness Diseases 0.000 description 1
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N Benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N C[N+](C)(C)CCO Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 230000037242 Cmax Effects 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N Diethylethanolamine Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- YIIMEMSDCNDGTB-UHFFFAOYSA-N Dimethylcarbamoyl chloride Chemical compound CN(C)C(Cl)=O YIIMEMSDCNDGTB-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- XBLVHTDFJBKJLG-UHFFFAOYSA-N Ethyl nicotinate Chemical compound CCOC(=O)C1=CC=CN=C1 XBLVHTDFJBKJLG-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N Fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- 229960002442 Glucosamine Drugs 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229940102223 Injectable Solution Drugs 0.000 description 1
- 229940044173 Iodine-125 Drugs 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 208000009856 Lung Disease Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N Methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N Methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 229910000949 MnO2 Inorganic materials 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000036913 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N N,N-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- RXFXGKDBNOKILL-UHFFFAOYSA-N N-(2-formylphenyl)imidazo[1,2-a]pyridine-8-carboxamide Chemical compound O=CC1=CC=CC=C1NC(=O)C1=CC=CN2C1=NC=C2 RXFXGKDBNOKILL-UHFFFAOYSA-N 0.000 description 1
- FEWLNYSYJNLUOO-UHFFFAOYSA-N N-Formylpiperidine Chemical compound O=CN1CCCCC1 FEWLNYSYJNLUOO-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 230000037164 Plasma conc Effects 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 206010038683 Respiratory disease Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229960004249 Sodium Acetate Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- 229960004559 Theobromine Drugs 0.000 description 1
- 230000035852 Tmax Effects 0.000 description 1
- 229940117013 Triethanolamine oleate Drugs 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N Trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 229940035504 Tromethamine Drugs 0.000 description 1
- 206010068760 Ulcers Diseases 0.000 description 1
- 230000036462 Unbound Effects 0.000 description 1
- 230000035969 Vmax Effects 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N Zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- FXKDDCBFUOGTQM-UHFFFAOYSA-N [2-(2-propan-2-ylpyrazol-3-yl)pyridin-3-yl]methanol Chemical compound CC(C)N1N=CC=C1C1=NC=CC=C1CO FXKDDCBFUOGTQM-UHFFFAOYSA-N 0.000 description 1
- QBRNSNZOUCVKKE-UHFFFAOYSA-N [2-[2-(2,2,2-trifluoroethyl)pyrazol-3-yl]pyridin-3-yl]methanol Chemical compound OCC1=CC=CN=C1C1=CC=NN1CC(F)(F)F QBRNSNZOUCVKKE-UHFFFAOYSA-N 0.000 description 1
- PFVCXUKCRUKBPB-UHFFFAOYSA-N [2-[2-(3,3,3-trifluoropropyl)pyrazol-3-yl]pyridin-3-yl]methanol Chemical compound OCC1=CC=CN=C1C1=CC=NN1CCC(F)(F)F PFVCXUKCRUKBPB-UHFFFAOYSA-N 0.000 description 1
- MYRWMZACSRRKFN-UHFFFAOYSA-N [6-(1-propan-2-ylpyrazol-3-yl)pyridin-3-yl]methanol Chemical compound CC(C)N1C=CC(C=2N=CC(CO)=CC=2)=N1 MYRWMZACSRRKFN-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- RXUBZLMIGSAPEJ-UHFFFAOYSA-N benzyl N-aminocarbamate Chemical compound NNC(=O)OCC1=CC=CC=C1 RXUBZLMIGSAPEJ-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 239000004305 biphenyl Chemical group 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- JAMFGQBENKSWOF-UHFFFAOYSA-N bromo(methoxy)methane Chemical compound COCBr JAMFGQBENKSWOF-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 229940042397 direct acting antivirals Cyclic amines Drugs 0.000 description 1
- CWHBCTLVWOCMPQ-UHFFFAOYSA-L disodium;2-[(3,5-diiodo-4-oxidophenyl)-(3,5-diiodo-4-oxocyclohexa-2,5-dien-1-ylidene)methyl]benzoate Chemical group [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C(C=1C=C(I)C([O-])=C(I)C=1)=C1C=C(I)C(=O)C(I)=C1 CWHBCTLVWOCMPQ-UHFFFAOYSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000001804 emulsifying Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- IXUVLJDKQGPXCK-UHFFFAOYSA-N ethyl 1H-imidazo[4,5-b]pyridine-2-carboxylate Chemical compound C1=CC=C2NC(C(=O)OCC)=NC2=N1 IXUVLJDKQGPXCK-UHFFFAOYSA-N 0.000 description 1
- KOAWFXMHARNHJY-UHFFFAOYSA-N ethyl 2-cyanopyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=CN=C1C#N KOAWFXMHARNHJY-UHFFFAOYSA-N 0.000 description 1
- YPRBNFRLIKIHST-UHFFFAOYSA-N ethyl 6-(aminomethyl)pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=C(CN)N=C1 YPRBNFRLIKIHST-UHFFFAOYSA-N 0.000 description 1
- OAUYNMCBOPUJCL-UHFFFAOYSA-N ethyl 6-cyanopyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=C(C#N)N=C1 OAUYNMCBOPUJCL-UHFFFAOYSA-N 0.000 description 1
- RUJPPJYDHHAEEK-UHFFFAOYSA-N ethyl piperidine-4-carboxylate Chemical compound CCOC(=O)C1CCNCC1 RUJPPJYDHHAEEK-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic Secondary and tertiary amines Drugs 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005291 haloalkenyloxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005292 haloalkynyloxy group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ILULYDJFTJKQAP-UHFFFAOYSA-N hydron;propan-2-ylhydrazine;chloride Chemical compound [Cl-].CC(C)N[NH3+] ILULYDJFTJKQAP-UHFFFAOYSA-N 0.000 description 1
- 230000001631 hypertensive Effects 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 150000002466 imines Chemical group 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N iodine atom Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000004552 isoquinolin-4-yl group Chemical group C1=NC=C(C2=CC=CC=C12)* 0.000 description 1
- 230000000155 isotopic Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- IHLVCKWPAMTVTG-UHFFFAOYSA-N lithium;carbanide Chemical compound [Li+].[CH3-] IHLVCKWPAMTVTG-UHFFFAOYSA-N 0.000 description 1
- AMCNGINELBODDW-UHFFFAOYSA-N lithium;triethylboron(1-) Chemical compound [Li+].CC[B-](CC)CC AMCNGINELBODDW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005649 metathesis reaction Methods 0.000 description 1
- NZZDEODTCXHCRS-UHFFFAOYSA-N methyl 2-aminopyridine-3-carboxylate Chemical compound COC(=O)C1=CC=CN=C1N NZZDEODTCXHCRS-UHFFFAOYSA-N 0.000 description 1
- YTQKJVLJTRNZLE-UHFFFAOYSA-N methyl 5-(chloromethyl)pyridine-3-carboxylate;hydrochloride Chemical compound Cl.COC(=O)C1=CN=CC(CCl)=C1 YTQKJVLJTRNZLE-UHFFFAOYSA-N 0.000 description 1
- XGZVLEAZGCUUPH-UHFFFAOYSA-N methylamino(methylimino)methanesulfonic acid Chemical compound CNC(=NC)S(O)(=O)=O XGZVLEAZGCUUPH-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229910003465 moissanite Inorganic materials 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- VSEAAEQOQBMPQF-UHFFFAOYSA-N morpholin-3-one Chemical compound O=C1COCCN1 VSEAAEQOQBMPQF-UHFFFAOYSA-N 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 239000002055 nanoplate Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000005445 natural product Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 125000005254 oxyacyl group Chemical group 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- LVOICKNPHXSSQM-UHFFFAOYSA-N prop-2-en-1-one Chemical compound C=C[C]=O LVOICKNPHXSSQM-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 230000001235 sensitizing Effects 0.000 description 1
- 231100000202 sensitizing Toxicity 0.000 description 1
- 229910010271 silicon carbide Inorganic materials 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Substances [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Inorganic materials [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 1
- DCQXTYAFFMSNNH-UHFFFAOYSA-M sodium;2-[bis(2-hydroxyethyl)amino]ethanol;acetate Chemical compound [Na+].CC([O-])=O.OCCN(CCO)CCO DCQXTYAFFMSNNH-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 230000003595 spectral Effects 0.000 description 1
- 230000000087 stabilizing Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000005338 substituted cycloalkoxy group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- IVQOVGKPEVFHHH-UHFFFAOYSA-N tert-butyl-dimethyl-[[2-[2-(3,3,3-trifluoropropyl)pyrazol-3-yl]pyridin-3-yl]methoxy]silane Chemical compound CC(C)(C)[Si](C)(C)OCC1=CC=CN=C1C1=CC=NN1CCC(F)(F)F IVQOVGKPEVFHHH-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- MYVIATVLJGTBFV-UHFFFAOYSA-M thiamine(1+) chloride Chemical compound [Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N MYVIATVLJGTBFV-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Abstract
Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
Description
SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUÉ OXYGENATION
REFERENCES TO RELATED APPLICATIONS .
The présent application claims priority to U.S. Provisional Application No. 61/581,053, filed December 28, 2011, and U.S. Provisional Application No. 61/661,320, filed June 18, 2012, the entirety of which are incorporated herein by référencé.
FIELD OF THE INVENTION
The présent invention generally relates to substituted benzaldehydes and derivat'.ves thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their préparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders médiate by hemoglobin and disorders that would benefit from increased tissue oxygénation.
BACKGROUND OF THE INVENTION
Hemoglobin (Hb) is a tetrameric protein in red blood cells that transports up to four oxygen molécules from the lungs to varions tissues and organs throughout the body.
Hemoglobin binds and releases oxygen through conformational changes, and is in the tense (T) State when it is unbound to oxygen and in the relaxed (R) State when it is bound to oxygen. The equilibrium between the two conformational States is under allosteric régulation. Natural compounds such as 2,3-bisphosphoglycerate (2,3-BPG), protons, and carbon dioxide stabilize hemoglobin in its de-oxygenated T State, while oxygen stabilizes hemoglobin in its oxygenated R State. Other relaxed R States hâve also been found, however their rôle in allosteric régulation has not been fully elucidated.
Sickle cell disease is a prévalent disease particularly among those of African and Mediterranean descent. Sickle hemoglobin (HbS) contains a point mutation where glutamic acid is replaced with valine, allowing the T State to become susceptible to polymerization to give the HbS containing red blood cells their characteristic sickle shape. The sickled cells are also more rigid than normal red blood cells, and their lack of flexibility can lead to blockage of blood vessels. Certain synthetic aldéhydes hâve been found to shift the equilibrium from the polymer forming T State to the non-polymer forming R State (Nnamani et al. Chemistry & Biodiversity Vol. 5,2008 pp. 1762-1769) by acting as allosteric modulators to stabilize the R State through formation of a Schiff base with an amino group on hemoglobin.
.....US 7,160,910 discloses 2-furfuraldehydes and related compounds that are also allosteric modulators of hemoglobin. One particular compound 5-hydroxymethyl-2-furfuraldehyde (5HMF) was found to be a potent hemoglobin modulator both in vitro and in vivo.
Transgenic mice producing human HbS that were treated with 5HMF were found to hâve 5 significantly improved survival times when exposed to extreme hypoxia (5% oxygen). Under these hypoxie conditions, the 5HMF treated mice were also found to hâve reduced amounts of hypoxia-induced sickled red blood cells as compared to the non-treated mice.
A need exists for therapeutics that can shift the equilibrium between the deoxygenated and oxygenated States of Hb to treat disorders that are mediated by Hb or by abnormal Hb such as 10 HbS. A need also exists for therapeutics to treat disorders that would benefit from having Hb in the R State with an increased affinity for oxygen. Such therapeutics would hâve applications ranging, for example, from sensitizing hypoxie tumor cells that are résistant to standard radiotherapy or chemotherapy due to the low levels of oxygen in the cell, to treating pulmonary and hypertensive disorders, and to promoting wound healing.
BRIEF SUMMARY OF THE INVENTION
The présent invention provides, in one aspect, allosteric modulators of hemoglobin. In another aspect, provided are pharmaceutical compositions comprising the allosteric modulators disclosed herein. In other aspects, provided are methods for treating disorders mediated by hemoglobin and methods for increasing tissue oxygénation for treating disorders 20 that would benefit from increased oxygénation, such methods comprising administering the allosteric modulators disclosed herein to a subject in need thereof. In still other aspects, provided are methods for preparing the allosteric modulators disclosed herein. These and other embodiments of the invention are more fully described in the description that follows.
DETAILED DESCRIPTION OF THE INVENTION
I. Définitions
As used herein, the below ternis hâve the following meanings unless specified otherwise.
The abbreviations used herein are conventional, unless otherwise defîned: aq = aqueous; Boc = t-butylcarboxy, (Boc)2O = di-fert-butyl dicarbonate, °C = degrees celcius, mCPBA = m. chloroperoxybenzoic acid, DCM = dichloromethane (CH2C12), DIBAL = diisobutylaluminum hydride, DMF = dimethyl formamide, EtOAc = ethyl acetate, g = gram, H2 = hydrogen; H2O = water; HBr = hydrogen bromide; HCl = hydrogen chloride, HPLC = high pressure liquid chromatography, h = hour, LAH = lithium aluminum hydride (LÎA1H4);
. . — - - , . . . . -. ». . .- . . . . . .· · ... . » - - — . ~ «... y ·-—- — ., ΙΧ·»—'
...... ........... 19779
MeCN = acetonitrile; MS = Mass Spectrum, m/z = mass to charge ratio, MHz ~ Mega Hertz, MeOH = methanol, μΜ = micromolar, pL = microliter, mg = milligram, mM = rnillimolar, mmol = millimole, mL = milliliter, min = minute, M - molar, Na2CO3 = sodium carbonate, ng = nanogram, N = Normal, NMR = nuclear magnetic résonance, Pd/C = palladium on carbon, rp = reverse phase, sat = saturated, rt = room température, TEA = triethylamine, THF = tetrahydrofuran, TFA = trifluoroacetic acid, TLC = thin layer chromatography, and TMS = trimethylsilyl.
It is noted here that as used in this spécification and the appended daims, the singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictâtes otherwise.
“Alkoxy” refers to -O(alkyl) where alkyl as defined herein. Représentative examples of alkoxy groups include methoxy, ethoxy, Abutoxy, and the like.
“Alkyl,” by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain, fully saturated aliphatic hydrocarbon radical having the number of carbon atoms designated. For example, “Ci.8alkyl” refers to a hydrocarbon radical straight or branched, containing from 1 to 8 carbon atoms that is derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane. Alkyl includes branched chain isomers of straight chain alkyl groups such as isopropyl, t-butyl, isobutyl, sec-butyl, and the like. Représentative alkyl groups include straight and branched chain alkyl groups having 1, 2,3,4, 5, 6,7, 8, 9,10, 11 or 12 carbon atoms. Further représentative alkyl groups include straight and branched chain alkyl groups having 1, 2, 3,4, 5, 6, 7 or 8 carbon atoms.
“Alkenyl” refers to a linear monovalent hydrocarbon radical or a branched monovalent hydrocarbon radical having the number of carbon atoms indicated in the prefix and containing at least one double bond, but no more than three double bonds. For example, C2. 8alkenyl is meant to include, ethenyl, propenyl, 1,3-butadienyl and the like.
“Alkynyl” means a linear monovalent hydrocarbon radical or a branched monovalent hydrocarbon radical containing at least one triple bond and having the number of carbon atoms indicated in the prefix. The term “alkynyl” is also meant to include those alkyl groups having one triple bond and one double bond. For example, C2-8alkynyl is meant to include ethynyl, propynyl and the like.
The term “allosteric modulators” refers to compounds that bind to hemoglobin to modulate its affinity for oxygen. In one group of embodiments, the allosteric modulators act to stabilize or destabilize a particular hemoglobin conformation. In one group of embodiments, the modulators stabilize the relaxed R State. In other embodiments, the modulators destabilize the tense T state. In one group of embodiments, the allosteric modulators can destabilize one conformation while stabilizing another. In some such embodiments, the modulators stabilize a relaxed R State and destabilize the tense T State. The modulators, in addition to modulating the affinity of hemoglobin for oxygen, may also confer additional properties to hemoglobin such as increasing its solubility. The présent disclosure is not intended to be limited to the mechanism by which the allosteric modulators interact with and regulate hemoglobin. In one group of embodiments, the allosteric modulators inhibit the polymerization of HbS and the sickling of red blood cells. In one group of embodiments, the binding of the allosteric modulators provided herein to hemoglobin can occur through covalent or non-covalent interactions. In one embodiment, the allosteric modulators react through its aldéhyde substituent with an amine group on a hemoglobin amino acid side chain to form a Schiff base.
“Amino” refers to a monovalent radical -NH2.
“Aryl” by itself or as part of another substituent refers to a polyunsaturated, aromatic, hydrocarbon group containing from 6 to 14 carbon atoms, which can be a single ring or multiple rings (up to three rings) which are fused together c<r linked covalently. Thus the phrase includes, but is not limited to, groups such as phenyl, biphenyl, anthracenyl, naphthyl by way of example. Non-limiting examples of aryl groups include phenyl, 1-naphthyl, 2-naphthyl and 4-biphenyl.
“Bond” when used as an element in a Markush group means that the corresponding group does not exist, and the groups of both sides are directly linked.
“Cycloalkyl” refers to a saturated or partially saturated cyclic group of from 3 to 14 carbon atoms and no ring heteroatoms and having a single ring or multiple rings including fused, bridged, and spiro ring Systems. The term “cycloalkyl” includes cycloalkenyl groups, a partially saturated cycloalkyl ring having at least one site of >C=C< ring unsaturation. Examples of cycloalkyl groups include, for instance, adamantyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, and cyclohexenyl. “Cu’.v’cycloalkyl” refers to cycloalkyl groups having u’ to v’ carbon atoms as ring members. “Cu’.V’cycloalkenyl” refers to cycloalkenyl groups having u’ to v’ carbon atoms as ring members.
The term “hemoglobin” as used herein refers to any hemoglobin protein, including normal hemoglobin (Hb) and sickle hemoglobin (HbS).
’
.................. ......-Tffînï· “Heteroaryl” refers to a cyclic or polycyclic radical having at least one aromatic ring and from one to five ring heteroatom selected from N, O, and S. and optionally one or more oxo (=O) substituents attached to one or more carbon ring atoms, and wherein the nitrogen and sulfur ring atoms are optionally oxidized. A heteroaryl group can be attached to the remainder of the molécule through a heteroatom or through a carbon atom and can contain 5 to 10 carbon atoms. Heteroaryl groups include polycyclic aromatic ring(s) fused to nonaromatic cycloalkyl or heterocycloalkyl groups, and where the point of attachment to the remainder of the molécule can be through any suitable ring atom of any ring. In a polycyclic heteroaryl group, the ring heteroatom(s) can be in either an aromatic or non-aromatic ring or both. The term “aromatic ring” include any ring having at least one planar résonance structure where 2n+2 pi électrons are delocalized about the ring. Examples of heteroaryl groups include, but are not limited to, imidazopyridinyl groups, pyrrolopyridinyl groups, pyrazolopyridinyl groups, triazolopyridinyl groups, pyrazolopyrazinyl groups, pyridinyl groups, pyrazinyl groups, oxazolyl groups, imidazolyl groups, triazolyl groups, tetrazolyl groups, pyrazolyl groups, quinolinyl groups, isoquinolinyl groups, indazolyl groups, benzooxazolyl groups, naphthyridinyl groups, and quinoxalinyl groups. Other non-limiting examples of heteroaryl groups include xanthine, hypoxanthine, 5-benzothiazolyl, purinyl, 2benzimidazolyl, benzopyrazolyl, 5-indolyl, azaindole, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, 6-quinolyl 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 1pyrazolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 5oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl and 4pyrimidyl. “Bicyclic heteroaryl” refers to a heteroaryl radical that contains two rings.
The term “heterocycloalkyl” refers to a cycloalkyl group containing at least one ring heteroatom and optionally one or more oxo substituents. As used herein, the term “heteroatom” is meant to include oxygen (O), nitrogen (N), and sulfur (S), wherein the heteroatoms are optionally oxidized, and the nitrogen atom(s) are optionally quatemized. Each heterocycle can be attached at any available ring carbon or heteroatom. Each heterocycle may hâve one or more rings. When multiple rings are présent, they can be fused together. Each heterocycle typically contains 1,2, 3,4 or 5, independently selected heteroatoms. Preferably, these groups contain 1,2, 3,4, 5, 6,7, 8, 9 or 10 carbon atoms, 0,1, 2, 3,4 or 5 nitrogen atoms, 0,1 or 2 sulfur atoms and 0,1 or 2 oxygen atoms. More preferably, these groups contain 1,2 or 3 nitrogen atoms, 0-1 sulfur atoms and 0-1 oxygen atoms. Non-limiting examples of heterocycle groups include morpholin-3-one, piperazine-25 one, piperazin-1 -oxide, piperidine, morpholinc, piperazine, isoxazoline, pyrazohne, imidazoline, pyrrolidine, and the like.
“Halo” or “halogen” by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as “haloalkyl”, are meant to include alkyl in which one or more hydrogen is substituted with halogen atoms which can be the same or different, in a number ranging from one up to the maximum number of halogens permitted e.g. for alkyl, (2m'+l), where m'is the total number of carbon atoms in the alkyl group. For example, the term “haloCl-8alkyl” is meant to include difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromoprcpyl, and the like. The term “haloalkenyl”, and “haloalkynyl” refers to alkenyl and alkynyl radicals having one or more halogen atoms. Additionally, term “haloalkoxy” refers to an alkoxy radical substituted with one or more halogen atoms. In one group of embodiments, the haloakyl, haloalkenyl, haloalkynyl, and haloalkoxy groups hâve from one to 5 or from one to 3 halo atoms. Examples of haloalkoxy groups include difluoromethoxy and trifluoromethoxy. In one group of embodiments, the halo atoms of the haloalkenyl and haloalkynyl groups are attached to the aliphatic portions of these groups.
The terms “optional” or “optionally” as used throughout the spécification means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, “heteroaryl group optionally substituted with an alkyl group means that the alkyl may but need not be présent, and the description includes situations where the heteroaryl group is substituted with an alkyl group and situations where the heteroaryl group is not substituted with the alkyl group.
“Oxo” refers to the divalent atom =0.
In each of the above embodiments designating a number of atoms e.g. “Ci.g” is meant to include ail possible embodiments that hâve one fewer atom. Non-limiting examples include Cm, Ci-5, Ci-6, Ci-7, C2-8, C2.7, C3.8, C3.7 and the like.
The term “pharmaceutically acceptable salts” is meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the présent invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of salts derived from pharmaceutically-acceptable inorganic bases include aluminum, ammonium, calcium, copper, ferrie, ferrous, lithium, magnésium, manganic, manganous, potassium, sodium, zinc and the like. Salts derived from pharmaceutically-acceptable organic bases include salts of primary, secondary and tertiary amines, including substituted amines, cyclic amines, naturallyoccurring amines and the like, such as arginine, betaine, caffeine, choline, N,N’dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like. When compounds of the présent invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufïïcient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, malonic, benzoic, succinic, suberic, fumaric, mandelic, phthalic, benzenesulfonic,p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, e.g., Berge, S.M. et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Science, 66:1-19,1977). Certain spécifie compounds of the présent invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
The neutral forms of the compounds may be regenerated by contacting the sait with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various sait forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are équivalent to the parent form of the compound for the purposes of the présent invention.
The term “pharmaceutically acceptable carrier or excipient” means a carrier or excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes a carrier or excipient that is acceptable for veterinary use as well as human pharmaceutical use. A “pharmaceutically ' 7 ’ acceptable carrier or excipient” as used in the spécification and daims includes both one and more than one such carrier or excipient.
The terms “pharmaceutically effective amount”, “therapeutically effective amount” or “therapeutically effective dose” refers to the amount of the subject compound that will elicit the biological or medical response of a tissue, System, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician. The term “therapeutically effective amount” includes that amount of a compound that, when administered, is sufficient to prevent development of, or alleviate to some extent, one or more of the symptoms of the condition or disorder being treated. The therapeutically effective amount will vary depending on the compound, the disorder or condition and its severity and the âge, weight, etc., of the mammal to be treated.
“Protecting group” refers to a group of atoms that, when attached to a reactive functional group in a molécule, mask, reduce or prevent the reactivity of the functional group. Typically, a protecting group may be selectively removed as desired during the course of a synthesis. Examples of protecting groups can be found in Greene and Wuts, Protective Groups in Organic Chemistry, 3rd Ed., 1999, John Wiley & Sons, NY and Harrison et al., Compendium of Synthetic Organic Methods, Vols. 1-8,1971-1996, John Wiley & Sons, NY. Représentative amino protecting groups include, but are not limited to, formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl (“CBZ”), tert-butoxycarbonyl (“Boc”), trimethylsilyl (“TMS”), 2-trimethylsilyl-ethanesulfonyl (“TES”), trityl and substituted trityl groups, allyloxycarbonyl, 9-fluorenylmethyloxycarbonyl (“FMOC”), nitroveratryloxycarbonyl (“NVOC”) and the like. Représentative hydroxy protecting groups include, but are not limited to, those where the hydroxy group is either acylated or alkylated such as benzyl and trityl ethers, as well as alkyl ethers, tetrahydropyranyl ethers, trialkylsilyl ethers (e.g., TMS or TIPPS groups) and allyl ethers.
The term “aldéhyde protecting group” refers to any known protecting group used to mask the aldéhyde functionality. Aldéhyde protecting groups include acetals and hemiacetals. The acetals and hemiacetals can be prepared from Cps alcohols or C2-8 diols. In one group of embodiments, the aldéhyde protecting group is a five or six membered cyclic acetal formed from condensation of the aldéhyde with ethylene or propylene glycol. In another group of embodiments the aldéhyde protecting group is an imine or hydroxyimine. The aldéhyde protecting groups of the présent disclosure also include prodrug groups that convert the aldéhyde to a prodrug, where the aldéhyde is formed in vivo as the active agent under physiological conditions upon administration of the prodrug. The prodrug group can also 8 serve to increase the bioavailability of the aldéhyde. In one group of embodiments, the prodrug group is hydrolyzed in vivo to the aldéhyde. In one group of embodiments, the aldéhyde protecting group is a thiazolidine or N-acetylthiazolidine prodrug group. In one group of embodiments, the aldéhyde protecting group is a thiazolidine prodrug group disclosed in US 6,355,661. In one group of embodiments the modulators provided herein are condensed with L-cysteine or a L-cysteine dérivative to form the corresponding thiazolidine protected aldéhyde prodrug. In one group of embodiments, the thiazolidine has the formula wherein R11 is selected from the group consisting of OH, alkoxy, substituted alkoxy, cycloalkoxy, substituted cycloalkoxy, aryloxy, substituted aryloxy, heteroaryloxy, substituted heteroaryloxy, N(RI3)2 where R13 is independently H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; R is H or L-R14, where L is carbonyl or sulfonyl; R14 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; the wavy line signifies the point of attachment to the phenyl ring of the allosteric modulators disclosed herein; and the term “substituted” refers to substitution by one or more substituents selected from the group consisting of COOH, CHO, oxyacyl, acyloxy, cycloacyloxy, phénol, phenoxy, pyridinyl, pyrrolidinyl, amino, amido, hydroxy, alkoxy, cycloalkoxy, F, Cl, Br, NO2, cyano, sulfuryl, and the like. In one group of embodiments, provided are modulators having a thiazolidine protecting group where R11 is alkoxy and R12 is H, or where Rn is OH and R12 is -C(O)alkyl, or where R11 is NH(heteroaryl) and R12 is -C(O)alkyl.
The term “sickle cell disease” refers to diseases mediated by sickle hemoglobin (HbS) that results from a single point mutation in the hemoglobin (Hb). Sickle cell diseases includes sickle cell anémia, sickle-hemoglobin C disease (HbSC), sickle beta-plus- (HbS/β*) and sickle beta-zero-thalassaemia (HbS/β0).
The “subject” is defined herein to include animais such as mammals, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice and the like. In preferred embodiments, the subject is a human.
“Tautomer” refers to altemate forms of a molécule that differ in the position of a proton, such as enol-keto and imine-enamine tautomers, or the tautomeric forms of heteroaryl groups containing a -N=C(H)-NH- ring atom arrangement, such as pyrazoles, imidazoles, benzimidazoles, triazoles, and tetrazoles. A person of ordinary skill in the art would recognize that other tautomeric ring atom arrangements are possible.
The ternis “treat”, “treating”, “treatment” and grammatical variations thereof as used herein, includes partially or completely delaying, alleviating, mitigating or reducing the intensity, progression, or worsening of one or more attendant symptoms of a disorder or condition and/or alleviating, mitigating or impeding one or more causes of a disorder or condition. Treatments according to the invention may be applied preventively, prophylactically, ' pallatively or remedially.
The symbol > when used in connection with a substituent signifies that the substituent is a divalent substituent attached to two different atoms through a single atom on the substituent.
The term “wavy line” signifies the point of attachment of the substituent to the remainder of the molécule. When the wavy line is not depicted as being specifically appended to a spécifie ring atom, the point of attachment can be to any suitable atom of the substituent. For example, the wavy line in the following structure:
is intended to include, as the point of attachment, any of the six substitutable carbon atoms.
Compounds that hâve the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers”. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers”. “Stereoisomer” and “stereoisomers” refer to compounds that exist in different stereoisomeric forms if they possess one or more asymmetric centers or a double bond with asymmetric substitution and, therefore, can be produced as individual stereoisomers or as mixtures. Stereoisomers include enantiomers and diastereomers. Stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers”. When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molécule rotâtes the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a “racemic mixture”. Unless otherwise indicated, the description is intended to include individual stereoisomers as well as mixtures. The methods for the détermination of stereochemistry and the séparation of stereoisomers are well-known in the art (see discussion in Chapter 4 of Advanced Organic Chemistry, 4th édition J.
March, John Wiley and Sons, New York, 1992) differ in the chirality of one or more stereocenters.
The compounds of the présent invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with isotopes, such as for example deuterium ( H), tritium (3H), iodine-125 (,25I) or carbon-14 (14C). Ail isotopic variations of the compounds of the présent invention, whether radioactive or not, are intended to be encompassed within the scope of the présent invention.
Unless indicated otherwise, the nomenclature of substituents that are not explicitly defined herein are arrived at by naming the terminal portion of the functionality followed by the adjacent functionality toward the point of attachment. For example, the substituent “alkoxyalkyl” refers to an akyl group that is substituted with alkoxy and “hydoxyalkyl” refers to an akyl group that is substituted with hydroxy. For both of these substituents, the point of attachment is at the alkyl group.
It is understood that the définitions and formulas provided herein are not intended to include impermissible substitution patterns (e.g., methyl substituted with 5 fluoro groups). Such impermissible substitution patterns are well known to the skilled artisan.
IL Hemoglobin modulators
In one group of embodiments, provided is a compound of Formula (I):
(I) or a tautomer or pharmaceutically acceptable sait thereof, wherein Q is selected from the group consisting of aryl, heteroaryl, and heterocycloalkyl, each optionally substituted with one to three Ra;
Y is O or CRlaRlb, where Rla is H or halo and RIb is selected from the group consisting of H, halo, and OH;
X is selected from the group consisting of O, >CH(CH2)nR8, and C(R9)2 where n is 0 or 1, R8 is OH, and R9 is independently H or halo; or Y-X taken together is -NHC(O)- or C(O)NH-;
R2, R3, R4, and R5 are independently selected from the group consisting of hydrogen, halo, Rb, ORd, O(CH2)zORd, O(CH2)zNRdRd, OC(O)Re, SRd, CN, NO2, CO2Rd, CONRdRd, 11 ’
C(O)Rd, OC(O)NRdRd, NRdRd, NRdC(O)Re, NRdC(O)2Re, NRdC(O)NRdRd, S(O)RC, S(O)2Re, NRdS(O)2Re, S(O)2NRdRd, and N3, where z is 0, 1, 2, 3,4, 5. or 6; or R5 is -(CH2)pR5a where p is 0 or 1 and R5a is OH;
R6 and R7 together form oxo or an aldéhyde protecting group, or R6 together with Rlb, R8, or R5 forms a cyclic ether where one of Rlb, R8, or R5a is O, R6 is a bond, and R7 is selected from the group consisting of OH, C].8alkoxy, and haloCi.8alkoxy;
each Ra is independently selected from the group consisting of halo, Rb, ORd, O(CH2)uORd, O(CH2)uNRdRd, O(CH2)uNRdC(O)Re, O(CH2)uNRdC(O)2Re, O(CH2)uNRdS(O)2Re, NH2, -(CH2)kOC(O)Re, -(CH2)kSRd, CN, NO2, -(CH2)kCO2(C,. 8alkyl)OH, -(CH2)kCO2(Ci.8alkyl)(heteroaryl)C(OX -(CH2)kCO2Rd,
-(CH2)kCONRdRd, -(CH2)kNRdC(O)Re, -(CH2)kNRdC(O)2Re, -(CH2)kC(O)Rd, -(CH2)kOC(O)NRdRd, -NRd(CH2)uORd, -NRd(CH2)uNRdRd, -NRd(CH2)uNRdC(O)Re, , -NRd(CH2)uNRdC(O)2Re, -NRd(CH2)uNRdS(O)2Re, -(CH2)kNRdC(O)Re, -(CH2)kNRdC(O)2Rd, -(CH2)kNRdC(O)NRdRd, -(CH2)kS(O)Re, -(CH2)kS(O)2Re, -(CH2)kNRdS(O)2Re, -(CH2)kS(O)2NRdRd, N3, -(CH2)karyl optionally substituted with one to three Rc, -NRd(CH2)karyl optionally substituted with one to three Rc, -(CH2)kheteroaryl optionally substituted with one to three Rc, -NRd(CH2)kheteroaryl optionally substituted with one to three Rc, -(CH2)kheterocycloalkyl optionally substituted with one to three Rc, and -NRd(CH2)kheterocycloalkyl optionally substituted with one to three Rc where k is 0,1, 2, 3, 4, 5, or 6 and u is 1,2,3,4,5, or 6;
each Rb is independently selected from the group consisting of Ci-8alkyl, C2.8alkenyl, and C2.8 alkynyl, each optionally independently substituted with one to three halo, ORd, or NRdRd;
each Rc is independently selected from the group consisting of halo, Ci-8alkyl, haloCi. 8alkyl, C2.8alkenyl, haloC2.8 alkenyl, C2.8alkynyl, haloC2.8alkynyl, (CH2)mORf, OC(O)RS, SRf, CN, NO2, CO2Rf, CONRfRf, C(O)Rf, OC(O)NRfRf, (CH2)mNRfRf, NRfC(O)Rs, NRfC(O)2R8, NRfC(O)NRfRf, S(O)Rg, S(O)2Rg, NRfS(O)2Rg, S(O)2NRfRf, N3, heteroaryl optionally substituted with one to three Rh, and heterocycloalkyl optionally substituted with one to three Rh where m is selected from the group consisting of 0,1,2,3,4, 5, and 6;
each Rh is independently selected from the group consisting of halo, C].8alkyl, haloCi. 8alkyl, ORj, OC(O)R, SRj, NO2, CO2Rj, CONRjRj, C(O)Rj, OC(O)NRjRj, NRjRj, NRjC(O)R‘, NRjC(O)2R‘, NRjC(O)NRjRj, S(O)Rl, S(O)2R‘, NRjS(O)2Rl, and S(O)2NRjRj;
Rd, Rf, and RJ are each is independently selected from the group consisting of hydrogen, Ci-s alkyl, haloCi.galkyl, C2.8 alkenyl, haloC2-saIkenyl, C2.8 alkynyl, and haloC2salkynyl; and
Re, R8, and R‘ are each is independently selected from the group consisting of Ci. 8alkyl, haloCj-salkyl, C2-8 alkenyl, haloC2-8alkenyl, C2-8 alkynyl, and haloC2-8alkynyl.
In one group of embodiments, X and Y are not both O.
In one group of embodiments, when X is O, Rlb is not OH.
In one group of embodiments, when Y is O, and n is 0, R is not OH.
In one group of embodiments, when R6 and R7 together are oxo, Y is CH2, X is O or CH2, and R5 is H, halo, OH, CHO, or OCH3, then Q is V or W.
In one group of embodiments, V is selected from the group consisting of ,,,,,,, X ,,,,,,,,,,,,,, and naphthalene containing three to four ring nitrogen atoms; wherein V is optionally substituted with one to three Ra; and
W is selected from the group consisting of pyridin-2-yl, pyridin-3-yl, and pyridine-4yl,,,,,,, and , wherein W is optionally substituted with one to three Ra or is substituted with one to three Ra when W is pyridin-2-yl, pyridin-3-yl, or pyridine-4-yl, and wherein the wavy line signifies the point of attachment to Y, provided that when V is optionally substituted with one Ra, then at least one of R2, R3, R4, and R5 is ORd; and provided that when V is ,,,,„,, or, then V is substituted with one to three Ra.
In one group of embodiments, z is 0. In another group of embodiments, z is 1. In yet another group of embodiments, z is 2. In still another group of embodiments, z is 3. In another group of embodiments, z is 4. In yet another group of embodiments, z is 5. In still another group of embodiments, z is 6.
In one group of embodiments, provided is a compound of Formula (la):
Q I YX R6 R7 r2J\Xh XX R3^Y^R5 R4 (la) or a tautomer or pharmaceutically acceptable sait thereof, wherein Q is selected from the group consisting of aryl, heteroaryl, and heterocycloalkyl, each optionally substituted with one to three Ra;
Y is O or CRlaRlb, where Rla is H or halo and Rlb is selected from the group consisting of H, halo, and OH;
X is selected from the group consisting of O, >CH(CH2)nR8, and C(R9)2 where n is 0 or 1, R8 is OH, and R9 is independently H or halo;
R2, R3, R4, and R5 are independently selected from the group consisting of hydrogen, halo, Rb, ORd, OC(O)Re, SRd, CN, NO2, CO2Rd, CONRdRd, C(O)Rd, OC(O)NRdRd, NRdRd, NRdC(O)Re, NRdC(O)2Re, NRdC(O)NRdRd, S(O)Re, S(O)2Re, NRdS(O)2Re, S(O)2NRdRd, and N3; or R5 is -(CH2)pR5a where p is 0 or 1 and R5a is OH;
R6 and R7 together form oxo or an aldéhyde protecting group, or R6 together with Rlb, R8, or R5 forms a cyclic ether where one of Rlb, R8, or R5a is -O-, R6 is a bond, and R7 is selected from the group consisting of OH, Cpgalkoxy, and haloCi-galkoxy;
each Ra is independently selected from the group consisting of halo, Rb, ORd, OC(O)Re, SRd, CN, NO2, CO2Rd, CONRdRd, C(O)Rd, OC(O)NRdRd, NRdC(O)Re, NRdC(O)2Rd, NRdC(O)NRdRd, S(O)Re, S(O)2Re, NRdS(O)2Re, S(O)2NRdRd, N3, aryl optionally substituted with one to three Rc, heteroaryl optionally substituted with one to three Rc, and heterocycloalkyl optionally substituted with one to three Rc;
each Rb is independently selected from the group consisting of Cpsalkyl, C2-8alkenyl, -and C2-8 alkynyl, each optionally independently substituted with one to three halo, ORd, or NRdRd;
each Rc is independently selected from the group consisting of halo, Ci-salkyl, halo Cusalkyl, C2-salkenyl, haloC2-8 alkenyl, C2-8alkynyl, haloC2-8alkynyl, (CH2)mORf, OC(O)R8, SRf, CN, NO2, CO2Rf, CONRfRf, C(O)Rf, OC(O)NRfRf, (CH2)mNRfRf, NRfC(O)Rg,
NRfC(O)2R£, NRfC(O)NRrRf, S(O)Rs, S(O)2RE, NRfS(O)2Rg, S(O)2NRfRf, and N3 where m is selected from the group consisting of 0, 1,2, 3,4, 5, and 6;
each Rd and Rf is independently selected from the group consisting of hydrogen, Cj-8 alkyl, haloCi-salkyl, C2-8 alkenyl, haloC2-salkenyl, C2.8 alkynyl, and haloC2-8alkynyl; and each Re and Rs is independently selected from the group consisting of Cpsalkyl, haloCi-salkyl, C2.8 alkenyl, haloC2-8alkenyl, C2.8 alkynyl, and haloC2-salkynyl;
provided that X and Y are not both O;
provided that when X is O, R.lb is not OH;
provided that when Y is O, and n is 0, R8 is not OH; and provided that when R6 and R7 together are oxo, Y is CH2, X is O or CH2, and R' is H, halo, OH, CHO, or OCH3, then Q is V or W;
V is selected from the group consisting of
and naphthalene containing three to four ring nitrogen atoms; wherein V is optionally substituted with one to three Ra; and
-- · ..- -. . --- - - — — -- - ,- — · . * ... — . · r MI -ni II 1 M « -. — — —» i· Μ I — M..— « ......... ..... :....... ........ ........ 19779
W is selected from the group consisting of pyridin-2-yl, pyridin-3-yl, and pyridine-4N'N N~N %\J N-^ C\J M yl,, X, and , wherein W is optionally substituted with one to three Ra or is substituted with one to three Ra when W is pyridin-2-yl, pyridin-3-yl, or pyridine-4-yl, and wherein the wavy line signifies the point of attachment to Y, provided that when V is
O N.
Γ1 ΝΎ optionally substituted with one Ra, then at least one of R2, R3, R4, and R5 is 0Rd.
In one group of embodiments when R6 and R7 together are oxo, Y is CH2, X is O or CH2, and
R5 is H, halo, OH, CHO, or OCH3, Q is not
In one group of embodiments, R6 and R7 together form oxo.
In one group of embodiments, R6 and R7 together form a thiazolidine.
In one group of embodiments, z is 0. In another group of embodiments, z is 1. In yet another group of embodiments, z is 2. In still another group of embodiments, z is 3. In another group of embodiments, z is 4. In yet another group of embodiments, z is 5. In still another group of embodiments, z is 6.
In one group of embodiments, provided is a compound having Formula (le), (Id), or (le):
(le) (Id) (le) or a tautomer or pharmaceutically acceptable sait thereof, wherein R10 is selected from the group consisting of H, Ci.galkyl, and haloCj-galkyl. ·
In one group of embodiments, Q is a heteroaryl or heterocycloalkyl group optionally substituted with one to three Ra.
In one group of embodiments, Q is a bicyclic heteroaryl or heterocycloalkyl group optionally substituted with one to three Ra.
In one group of embodiments, Q is a bicyclic heteroaryl group optionally substituted with one to three Ra.In one group of embodiments, Q is isoquinolin-4-yl optionally substituted with one to three Ra wherein at least one Ra is heteroaryl optionally substituted with one to three Rc. In one group of embodiments at least one Ra is heteroaryl attached to said Q at the ring atom adjacent to ring atom bearing Y. In one group of embodiments at least one Ra is heteroaryl substituted with at least one Ci-galkyl. In one group of embodiments at least one Ra heteroaryl is substituted with at least one methyl. In one group of embodiments at least one Ra is pyrazolyl substituted with at least one Ci-galkyl. In one group of embodiments at least one Ra is pyrazoyl substituted with at least one methyl. In one group of embodiments, Ra is pyrazol-5-yl. In one group of embodiments, Ra is 4-methyl-pyrazol-5-yl.
In one group of embodiments, Q is a bicyclic heteroaryl group substituted with one to three Ra.
In one group of embodiments, Q is V.
In one group of embodiments, V is selected from the group consisting of ,,,,,,,,,,,, and , wherein V is optionally substituted with one to three Ra. In one group of embodiments, Q is substituted with CONRdRd, NRdRd, or heteroaryl optionally substituted with one to three Rc. In one group of embodiments, Q is substituted with heteroaryl having one to two nitrogen ring atoms.
In one group of embodiments, Q is W.
In one group of embodiments, Q is selected from the group consisting of ,, ,,,,,,,and .
In one group embodiments, at least one Ra is heteroaryl optionally substituted with one to three Rc.
• In one group of embodiments at least one Ra is heteroaryl attached to Q at the ring atom adjacent to ring atom bearing Y.
In one group of embodiments at least one Ra is heteroaryl substituted with at least one Ci8alkyl. In one group of embodiments at least one Ra heteroaryl is substituted with at least one methyl.
In one group of embodiments at least one Ra is pyrazolyl substituted with at least one Ci. 8alkyl. In one group of embodiments at least one Ra is pyrazoyl substituted with at least one Ci.8alkyl. In one group of embodiments, at least one Ra is pyrazol-5-yl. In one group of embodiments, at least one Ra is 4-methyl-pyrazol-5-yl.
In one group of embodiments, Q is pyridin-2-yl, pyridin-3-yl, or pyridine-4-yl, said Q is optionally substituted with one to three Ra wherein at least one Ra is heteroaryl optionally substituted with one to three Rc. In one group of embodiments at least one Ra is heteroaryl attached to said Q at the ring atom adjacent to ring atom bearing Y. In one group of embodiments at least one Ra is heteroaryl substituted with at least one Ci-8alkyl. In one group of embodiments at least one Ra heteroaryl is substituted with at least one methyl. In one group of embodiments at least one Ra is pyrazolyl substituted with at least one Ci.8alkyl. In one group of embodiments at least one R.a is pyrazoyl substituted with at least one methyl. In one group of embodiments, Ra is pyrazol-5-yl. In one group of embodiments, Ra is 4-methylpyrazol-5-yl.
In one group of embodiments, Q is substituted with at least one Ra selected from the group consisting of -(CH2)kOH, -(CH2)kNH2, -(CH2)kNH(Ci.8alkyl), -(CH2)kN(Ci.8alkyl)(Ci-8alkyl), -(CH2)kNHC(O)(C1.8alkyl), -(CH2)kN(C1.8alkyl)C(O)(Ci-8alkyl), -(CH2)kNHC(O)2(C1.8alkyl), -(CH2)kN(C1.8alkyl)C(O)2(Ci.8alkyl), -(CH2)kNHS(O)2(Ci.8alkyl), -(CH2)kN(Cj.
8alkyl)S(O)2(C].8alkyl), and -(CH2)kheterocycloalkyl optionally substituted with one to three Rc. In some embodiments the heterocycloalkyl group is morpholino or piperazinyl optionally substituted with alkyl, -C(O)Ci.8alkyl, -C(O)2Ci-8alkyl, or -S(O)2Ci-8alkyl.
In one group of embodiments, Q is substituted with at least one Ra selected from the group consisting of-NRd(CH2)uOH, -NRd(CH2)uNH2, -NRd(CH2)uNH(Ci.8alkyl), -NRd(CH2)uN(Ci. 8alkyl)(Ci.8alkyl),-NRd(CH2)uNHC(O)(Ci.8alkyl),-NRd(CH2)uN(Ci.8alkyl)C(O)(Ci.8alkyl), -NRd(CH2)uNHC(O)2(Ci.8alkyl), -NRd(CH2)uN(C1.8alkyl)C(O)2(Ci.8alkyl), -NRd(CH2)uNHS(O)2(C1.8alkyl), -NRd(CH2)uN(Ci.8alkyl)S(O)2(C1.8alkyl), and -NRd(CH2)kheterocycloalkyl optionally substituted with one to three Rc where u is 1, 2, 3,4, 5, or 6 and k is 0,1,2, 3,4, 5, or 6. In some embodiments, Rd is H or Ci.8alkyl. In some
embodiments the heterocycloalkyl group is morpholino or piperazinyl optionally substituted with alkyl, -C(O)Ci.8alkyl, -C(O)2C].8alkyl, or -S(O)2Ci.8alkyl.
In one group of embodiments, Q is substituted with at least one Ra selected from the group consisting of O(CH2)UOH, O(CH2)UNH2, O(CH2)uNH(Ci-8alkyl), O(CH2)uN(Ci-8alkyl)(Ci. 8alkyl), O(CH2)uNHC(O)(Ci.8alkyl), O(CH2)uN(Ci.8alkyl)C(O)(C ^alkyl), O(CH2)uNHC(O)2(Ci.8alkyl), O(CH2)uN(Ci.8alkyl)C(O)2(C1.8alkyl), O(CH2)uNHS(O)2(Ci. 8alkyl), O(CH2)uN(Ci-8alkyl)S(O)2(Ci.8alkyl), and O(CH2)uheterocycloalkyl optionally substituted with one to three Rc where u is 1, 2, 3,4, 5, or 6. In some embodiments the heterocycloalkyl group is morpholino or piperazinyl optionally substituted with alkyl, -C(O)Ci.8alkyl, -C(O)2Ci.8alkyl, or -S(O)2Ci.8alkyl.
In one group of embodiments, W is pyridin-2-yl, pyridin-3-yl, or pyridine-4-yl, said W substituted with CN or CONRdRd.
In one group of embodiments, R is H.
In one group of embodiments, R is H.
In one group of embodiments, R5 is H.
In one group of embodiments, R4 is Ci.8alkoxy.
In one group of embodiments, R2, R3, R’ are H and R4 is C].8alkoxy.
In one group of embodiments, R4 is methoxy.
In one group of embodiments, R4 is haloalkoxy. In one group of embodiments, R4 is OCHF2. In one group of embodiments, R4 is OCF3.
In one group of embodiments, R2, R3, R4, and R5 are H.
In one group of embodiments, one of R2, R3, R4, and R5 is selected from the group consisting of-O(CH2)zOH, -O(CH2)zO(Ci.8alkyl), -O(CH2)ZNH2, -OCCH^NHCCpgalkyl), and -O(CH2)zN(Ci.8alkyl)(C].8alkyl) where z is 0,1,2,3,4, 5, or 6.
In one group of embodiments, X is O.
In one group of embodiments, X is CH2.
In one group of embodiments, X is C(R9)2 and at least one of R9 is F. .
In one group of embodiments, Y is CH2.
In one group of embodiments, Y is CRlaRlb and at least one of Rla orRlbis F.
In one group of embodiments, z is 0. In another group of embodiments, z is 1. In yet another group of embodiments, z is 2. In still another group of embodiments, z is 3. In another group of embodiments, z is 4. In yet another group of embodiments, z is 5. In still another group of embodiments, z is 6.
In other embodiments, the invention provide a compound according to Formula (Ib):
Q I Y^X R6 R7
or a tautomer or pharmaceutically acceptable sait thereof, wherein Q is selected from the group consisting of aryl, heteroaryl, and heterocycloalkyl, each optionally substituted with one to three Ra;
Y is O or CH2;
X is O or CH2;
R2 and R3 are independently selected from the group consisting of hydrogen, halo, Rb, ORd, -O(CH2)zORd, -O(CH2)zNRdRd, OC(O)Re, SRd, CN, NO2, CO2Rd, CONRdRd, C(O)Rd, OC(O)NRdRd, NRdRd, NRdC(O)Re, NRdC(O)2Re, NRdC(O)NRdRd, S(O)Re, S(O)2Re, NRdS(O)2Re, S(O)2NRdRd, and N3, where z is 0,1,2, 3,4,5, or 6; or R5 is -(CH2)pR5a where p is 0 or 1 and R5a is OH;
R4 is selected from the group consisting of hydrogen and ORd;
R5 is selected from the group consisting of hydrogen, halo, and ORd;
R6 and R7 together form oxo or an aldéhyde protecting group;
each Ra is independently selected from the group consisting of halo, Rb, ORd, O(CH2)uORd, O(CH2)uNRdRd, O(CH2)uNRdC(O)Re, O(CH2)uNRdC(O)2Re, O(CH2)uNRdS(O)2Re, NH2, -(CH2)kOC(O)Re, -(CH2)kSRd, CN, NO2, -(CH2)kCO2(C1. 8alkyl)OH, -(CH2)kCO2(Ci-8alkyl)(heteroaryl)C(O)(Ci.8alkyl), -(CH2)kCO2Rd, -(CH2)kCONRdRd, -(CH2)kNRdC(O)Re, -(CH2)kNRdC(O)2Re, -(CH2)kC(O)Rd, -(CH2)kOC(O)NRdRd, -NRd(CH2)uORd, -NRd(CH2)uNRdRd, -NRd(CH2)uNRdC(O)Re, -NRd(CH2)uNRdC(O)2Re, -NRd(CH2)uNRdS(O)2Re, -(CH2)kNRdC(O)Re, -(CH2)kNRdC(O)2Rd,
-(CH2)kNRdC(O)NRdRd, -(CH2)kS(O)Re, -(CH2)kS(O)2Re, -(CH2)kNRdS(O)2Re, -C(O)(CH2)kNRdS(O)2Re, -(CH2)kC(O)NRdS(O)2Re, -(CH2)kS(O)2NRdRd, N3, -(CH2)karyl optionally substituted with one to three Rc, -NRd(CH2)karyl optionally substituted with one to three Rc, -(CH2)kheteroaryl optionally substituted with one to three Rc, -NRd(CH2)kheteroaryl optionally substituted with one to three Rc, -(CH2)kheterocycloalkyl optionally substituted with one to three Rc, and -NRd(CH2)kheterocycloalkyl optionally substituted with one to three Rc where k is 0, 1,2, 3,4, 5, or 6 and u is 1, 2, 3, 4, 5, or 6;
each Rb is independently selected from the group consisting of Cj-salkyl, C2.salkenyl, and C2-8 alkynyl, each optionally independently substituted with one to three halo, ORd, or NRdRd;
each Rc is independently selected from the group consisting of halo, Ci-galkyl, haloC|. 8alkyl, C2.galkenyl, haloC2.galkenyl, C2.8alkynyl, haloC2.salkynyl. (CH2)mORf, OC(O)R8, SRf, CN, NO2, (CH2)mCO2Rf, CONRfRf, C(O)Rf, OC(O)NRfRf, (CH2)mNRfRf,NRfC(O)Rg, NRfC(O)2Rg, NRfC(O)NRfRf, S(O)Rg, S(O)2Rg, NRfS(O)2Rg, S(O)2NRfRf, N3, (Rf)mSiC,. salkyl, heteroaryl optionally substituted with one to three Rh, cycloalkyl optionally substituted with one to three Rh, and heterocycloalkyl optionally substituted with one to three Rh where m is selected from the group consisting of 0,1,2, 3,4, 5, and 6;
each Rh is independently selected from the group consisting of halo, Cpsalkyl, haloCi. 8alkyl, ORj, OC(O)R, SRj, NO2, CO2Rj, CONRjRj, C(O)Rj, OC(O)NRjRj, NRjRj, NRjC(O)Rl, NRjC(O)2R‘, NRjC(O)NRjRj, S(O)R‘, 8(0^^, NRjS(O)2Rt, and S(O)2NRjRj;
Rd, Rf, and Rj are each independently selected from the group consisting of hydrogen, Ci.8alkyl, haloCi.8alkyl, C2.8alkenyl, haloC2.8alkenyl, C2.8 alkynyl, and haloC2.8alkynyl; and
Re, Rg, and R' are each independently selected from the group consisting of Cpsalkyl, haloCi-salkyl, C2.s alkenyl, haIoC2.8alkenyl, C2.8 alkynyl, and haloC2.8alkynyl;
provided that X and Y are not both O;
provided that at least one of R4 and R5 is H;
provided that if R4 is ORd, then Q is not phenyl, pyridinyl, or imidazo[l,2-a]pyridin-2yl, Ra is not oxo, oxido, or halo, and X is O, provided that if R5 is ORd, then Ra is not oxo, oxido, or halo; and provided that if R2-R5 are H, then Q is not phenyl.
In one group of embodiments, the invention provides a compound of formula Ib, or a tautomer or pharmaceutically acceptable sait thereof, wherein R6 and R7 together form oxo.
In one group of embodiments, the invention provides a compound of formula Ib, or a tautomer or pharmaceutically acceptable sait thereof, wherein R5 is selected from the group consisting of hydrogen and ORd.
In one group of embodiments, the invention provides a compound of formula Ib, or a tautomer or pharmaceutically acceptable sait thereof, wherein R5 is selected from the group consisting of hydroxy and fluoro.
In one group of embodiments, the invention provides a compound of formula Ib, wherein R and R3 are independently selected from the group consisting of hydrogen, Rb, ORd, O(CH2)zORd, O(CH2)zNRdRd, OC(O)Re, CO2Rd, CONRdRd, and C(O)Rd, where z is 1,2, or
3.
In one group of embodiments, the invention provides a compound of formula Ib, wherein R and R3 are H.
In one group of embodiments, the invention provides a compound of formula Ib, wherein Q is selected from the group consisting of :
and wherein Q is optionally substituted with one to three Ra.
In one group of embodiments, the invention provides a compound of formula Ib, wherein Q is selected from the group consisting of an imidazopyridinyl group, a pyrrolopyridinyl group, a pyrazolopyridinyl group, a triazolopyridinyl group, a pyrazolopyrazinyl group, a pyridinyl group, a pyrazinyl group, an oxazolyl group, an imidazolyl group, a triazolyl group, a tetrazolyl group, a pyrazolyl group, a quinolinyl group, an isoquinolinyl group, and indazolyl group, a benzooxazolyl group, a naphthyridinyl group, a quinoxalinyl group; and wherein Q is optionally substituted with one to three Ra.
In one group of embodiments, the invention provides a compound of formula Ib, wherein z is 0. In another group of embodiments, z is 1. In yet another group of embodiments, z is 2. In still another group of embodiments, z is 3. In another group of embodiments, z is 4. In yet another group of embodiments, z is 5. In still another group of embodiments, z is 6.
In other embodiments, the invention provide a compound according to Formula le:
or a tautomer or pharmaceutically acceptable sait thereof, wherein:
Y is O or CH2;
X is O or CH2;
Q is selected from the group consisting of:
i) imidazopyridinyl, methylimidazopyridinyl, indazolyl, pyrrolopyridinyl, pyrrolopyrazinyl. pyrazolopyridinyl, pyrazolopyrazinyl, and quinolinyl, each of which is optionally substituted with one to three Ra; wherein
R2, R3, R4, and R5, are independently selected from the group consisting of hydrogen, halo, Rb, ORd, O(CH2)zORd, O(CH2)zNRdRd, OC(O)Re, SRd, CN, NO2, CO2Rd, CONRdRd, C(O)Rd, OC(O)NRdRd, NRdRd, NRdC(O)Re, NRdC(O)2Re, NRdC(O)NRdRd, S(O)Re, S(O)2Re, NRdS(O)2Re, S(O)2NRdRd, and N3 where z is 1,2. or 3; and ii) pyridinyl and piperidinyl, each of which is optionally substituted with one to three Ra; wherein
R2, R3, and R4 are independently selected from the group consisting of hydrogen, halo, Rb, ORd, O(CH2)zORd, O(CH2)zNRdRd, OC(O)Re, SRd, CN, NO2, CO2Rd, CONRdRd, C(O)Rd, OC(O)NRdRd, NRdRd, NRdC(O)Re, NRdC(O)2Re, NRdC(O)NRdRd, S(O)Re, S(O)2Re, NRdS(O)2Re, S(O)2NRdRd, and N3 where z is 1,2, or 3; and
R5 is selected from the group consisting of halo and ORd;
R6 and R7 together form oxo or an aldéhyde protecting group;
each Ra is independently selected from the group consisting of halo, oxo, Rb, ORd, O(CH2)uORd, O(CH2)uNRdRd, O(CH2)uNRdC(O)Re, O(CH2)uNRdC(O)2Re, ' O(CH2)uNRdS(O)2Re, NH2, -(CH2)kOC(O)Re, -(CH2)kSRd, CN, NO2, -(CH2)kCO2(C1. 8alkyl)OH, -(CH2)kCO2(Ci.8alkyl)(heteroaryl)C(O)(C1.8alkyl), -(CH2)kCO2Rd, -(CH2)kCONRdRd, -(CH2)kNRdC(O)Re, -(CH2)kNRdC(O)2Re, -(CH2)kC(O)Rd, -(CH2)kOC(O)NRdRd, -NRd(CH2)uORd, -NRd(CH2)uNRdRd, -NRd(CH2)uNRdC(O)Re, -NRd(CH2)uNRdC(O)2Re, -NRd(CH2)uNRdS(O)2Re, -(CH2)kNRdC(O)Re, -(CH2)kNRdC(O)2Rd, -(CH2)kNRdC(O)NRdRd, -(CH2)kS(O)Re, -(CH2)kS(O)2Re, -(CH2)kNRdS(O)2Re, -C(O)(CH2)kNRdS(O)2Re, -(CH2)kC(O)NRdS(O)2Re, -(CH2)kS(O)2NRdRd, N3, -(CH2)karyl optionally substituted with one to three Rc, -NRd(CH2)karyl optionally substituted with one to three Rc, -(CH2)kheteroaryl optionally substituted with one to three Rc, -NRd(CH2)kheteroaryl optionally substituted with one to three Rc, -(CH2)kheterocycloalkyl optionally substituted with one to three Rc, and -NRd(CH2)kheterocycloalkyl optionally substituted with one to three Rc where k is 0, 1,2, 3,4, 5, or 6 and u is 1,2, 3,4, 5, or 6;
each Rb is independently selected from the group consisting of Cpsalkyl, C2. 8alkenyl, and C2.8alkynyl, each optionally independently substituted with one to three halo, ORd, orNRdRd;
each Rc is independently selected from the group consisting of halo, Ci.8alkyl, haloCi.8alkyl, C2.8alkenyl, haloC2.8alkenyl, C2.8alkynyl, haloC2.8alkynyl, (CH2)mORf, OC(O)R8, SRf, CN, NO2, (CH2)mCO2Rf, CONRfRf, C(O)Rf, OC(O)NRfRf, (CH2)mNRfRf, NRfC(O)R8, NRfC(O)2R8, NRfC(O)NRfRf, S(O)R8, S(O)2Rg, NRfS(O)2R8, S(O)2NRfRf, N3, (Rf)mSiCi.8alkyl, heteroaryl optionally substituted with one to three Rh, cycloalkyl optionally substituted with one to three Rh, and heterocycloalkyl optionally substituted with one to three Rh where m is selected from the group consisting of 0, 1, 2, 3,4, 5, and 6;
each Rh is independently selected from the group consisting of halo, Ci-8alkyl, haloC^alkyl, ORj, OC(O)R, SRj, NO2, CO2Rj, CONRjRj, C(O)Rj, OC(O)NRjRj, NRjRj, NRjC(O)R‘, NRjC(O)2R‘, NRjC(O)NRjRj, S(O)Rl, S(O)2R‘, NRjS(O)2R‘, and S(O)2NRjRj;
Rd, Rf, and Rj are each independently selected from the group consisting of hydrogen, C(.8 alkyl, haloCi.8alkyl, C2.8alkenyl, haloC2.8alkenyl, C2.8alkynyl, and haloC2. 8alkynyl; and
Re, Rg, and R‘ are each independently selected from the group consisting of Ci8alkyl, haloC].8alkyl, C2.8 alkenyl, haloC2.8alkenyl, C2.8 alkynyl, and haloC2. 8alkynyl.
In one group of embodiments, the invention provides a compound of formula le, wherein Q is selected from the group consisting of imidazo[l,5-a]pyridin-8-yl, imidazo[l,5-a]pyridin-6-yl, imidazo[l,5-a]pyridin-5-yl, imidazo[l,2-a]pyridin-8-yl, imidazo[l,2-a]pyridin-7-yl, imidazo[l,2-a]pyridin-6-yI, imidazo[l,2-a]pyridin-5-yl, imidazo[l,2-a]pyridin-3-yl, 8methylimidazo[l,2-a]pyridin-2-yI, indazol-4-yl, pyrrolo[2,3-b]pyridin-4-yl, pyrrolo[l,2a]pyrazin-6-yl, pyrrolo[l,2-a]pyrazin-4-yl, pyrazolo[3,4-b]pyridin-4-yl, pyrazolo[l,5a]pyrazin-3-yl, and quinolin-5-yl, each of which is optionally substituted with one to three Ra.
In one group of embodiments, the invention provides a compound of formula le, wherein z is 1. In another group of embodiments, z is 2. In still another group of embodiments, z is 3.
In one group of embodiments, the invention provides a compound wherein: Y is CH2; and X is CH2.
1717 97^^
In one group of embodiments, the invention provides a compound of formula le, wherein R is selected from the group consisting of H and ORd:
R3 is selected from the group consisting of H, CN, halo, and ORd;
R4 is selected from the group consisting of H, CN, and ORd: and
R5 is H.
In one group of embodiments, the invention provides a compound of formula le, wherein R is methoxy.
In one group of embodiments, the invention provides a compound of formula le, wherein Q is selected from the group consisting of pyridine-3-yl and piperidin-l-yl.
In one group of embodiments, the invention provides a compound of formula le, wherein R5 is selected from the group consisting of hydroxy and fluoro.
In one group of embodiments, the invention provides a compound of formula le, wherein R6 and R7 together form oxo.
In one group of embodiments, a compound is selected from Table 1 below or a tautomer or pharmaceutically acceptable sait thereof.
Table
Compound | Structure | Name |
1 | 2-(imidazo[l ,2-a]pyridin-8- ylmethoxy)-5-methoxybenzaldehyde | |
2 | 4-formyl-3-(imidazo[l,2-a]pyridin-8ylmethoxy)benzonitrile | |
3 | 2-(imidazo[l ,2-a]pyridin-8- ylmethoxy)-4-methoxybenzaldehyde | |
4 | 2-(imidazo[l ,2-a]pyridin-6- ylmethoxy)-5-methoxybenzaldehyde | |
5 | 2-(imidazo[l ,2-a]pyridin-2- |
ylmethoxy)-5-methoxybenzaldehyde | ||
6 | 2-(imidazo[l,5-a]pyridin-8ylmethoxy)-4-methoxybenzaldehyde | |
7 | 2-(imidazo[l,5-a]pyridin-8ylmethoxy)-5 -methoxybenzaldehyde | |
8 | 2-(imidazo[l ,2-a]pyridin-7- ylmethoxy)-5-methoxybenzaldehyde | |
9 | 2-(imidazo[l,2-a]pyridin-3ylmethoxy)-5-methoxybenzaldehyde | |
10 | 5-methoxy-2-(quinolin-5ylmethoxy)benzaldehyde | |
11 | 5-bromo-2-(imidazo[l,2-a]pyridin-8ylmethoxy)benzaldehyde | |
12 | 4-chloro-2-(imidazo[l,2-a]pyridin-8ylmethoxy)benzaldehyde | |
13 | 2-(imidazo[l,2-a]pyridin-8ylmethoxy)benzaldehyde | |
14 | 4-fluoro-2-(imidazo[ 1,2-a]pyridin-8ylmethoxy)benzaldehyde | |
15 | 2-(imidazo[l,2-a]pyridin-8ylmethoxy)-3 -methoxy benzal dehyde | |
16 | 2-(imidazo[l ,2-a]pyridin-8ylmethoxy)-5 -methy Ibenzaldehyde | |
17 | 5-methoxy-2-(pyrrolo [ 1,2-a]pyrazin-4ylmethoxy)benzaldehyde | |
18 | 2-(imidazo [ 1,5-a]pyridin-6- ylmethoxy)-4-methoxybenzaldehyde | |
19 | 2-(imidazo[l ,5-a]pyridin-5ylmethoxy)-5 -methoxybenzaldehyde | |
20 | 3-formyl-4-(imidazo[l,5-a]pyridin-5ylmethoxy)benzonitrile | |
21 | 2-((lH-pyrrolo[2,3-b]pyridin-4- yl)methoxy)-5-methoxybenzaldehyde |
22 | 5-ethyl-2-(imidazo[l,2-a]pyridin-8ylmethoxy)benzaldehyde | |
23 | 5-methoxy-2-((l -methyl-1 H-indazol-4yl)methoxy)benzaldehyde | |
24 | 5-methoxy-2-((8-methylimidazo [ 1,2a]pyridin-2-yl)methoxy)benzaldehyde | |
25 | 2-(( 1 H-indazol-4-yl)methoxy)-5methoxybenzaldehyde | |
26 | 2-(( 1 H-pyrrolo [2,3-b] pyridin-4yl)methoxy)-5-methoxybenzaldehyde | |
27 | 3-formyl-4-(imidazo[l,2-a]pyridin-8ylmethoxy)benzonitrile | |
28 | 5-methoxy-2-(pyrroIo[l,2-a]pyrazin-6ylmethoxy)benzaldehyde | |
29 | 6-((2-formyl-4- methoxyphenoxy)methyl)pyrrolo[l,2a]pyrazine-7-carbonitrile | |
30 | 6-((2-formyl-4- methoxyphenoxy)methyl)pyrrolo[ 1,2a]pyrazine-7-carboxamide | |
31 | 2-((lH-pyrazolo[3,4-b]pyridin-4- yl)methoxy)-5-methoxybenzaldehyde | |
32 | 5 -methoxy-2-(pyrazolo [ 1,5-a] pyrazin- 3 -ylmethoxy)benzaldehyde | |
33 | 5-methoxy-2-(pyrrolo[l,2-a]pyrazin-6ylmethoxy)benzaldehyde | |
34 | 2-(imidazo[l ,5-a]pyridin-6- ylmethoxy)-5-methoxybenzaldehyde | |
35 | 3-formyl-4-(imidazo[l,2-a]pyridin-8ylmethoxy)benzonitril e | |
36 | 3-(imidazo[l ,2-a]pyridin-8-ylmethyl)1,3-dihydroisobenzofuran-l -ol | |
37 | 2-(imidazo[l,2-a]pyridin-5ylmethoxy)-5-methoxybenzaldehyde |
38 | N-(2-formyl-4methoxyphenyl)imidazo[l ,2a]pyridine-8-carboxamide | |
39 | N-(2-formylphenyl)imidazo[ 1,2a]pyridine-8-carboxamide | |
40 | 2-formyl-N-(imidazo[l,2-a]pyridin-8yl)benzamide | |
41 | 5-methoxy-2-(pyridin-3ylmethoxy)benzaldehyde | |
42 | 4-((2-formyl-3- hydroxyphenoxy)methyl)benzoic acid | |
43 | 2-hydroxy-6-((2-( 1 -isopropyl-1Hpyrazol-5-yl)pyridin-3yl )methoxy)benzaldehyde | |
44 | 2-((3-(2H-tetrazol-5-yl)benzyl)oxy)-6hydroxybenzaldehyde | |
45 | 2-((4-(2H-tetrazol-5-yl)benzyl)oxy)-6hydroxybenzaldehyde | |
46 | methyl 4-((2- formylphenoxy)methyl)benzoate | |
47 | 4-((2-formylphenoxy)methyl)benzoic acid | |
48 | methyl 3-((2- formylphenoxy)methyl)benzoate | |
49 | 2-bromo-3-((2-( 1 -isopropyl-1Hpyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde | |
50 | 2-hydroxy-6-((2-( 1 -(2,2,2- trifluoroethyl)-1 H-pyrazol-5-yl)pyridin- 3-yl)methoxy)benzaldehyde | |
51 | 2-hydroxy-6-((2-(l -(3,3,3trifluoropropyl)-1 H-pyrazol-5 yl)pyridin-3-yl)methoxy)benzaldehyde | |
52 | 2-fluoro-6-((2-( 1 -(2,2,2-trifluoroethyl)lH-pyrazol-5-yl)pyridin-3- |
yl)methoxy)benzaldehyde | |
53 | 2-fluoro-6-((2-(l-(3,3,3- trifluoropropyl)-1 H-pyrazol-5- yl)pyridin-3-yl)methoxy)benzaldehyde |
54 | 2-fluoro-6-((2-(l -isopropyl-1Hpyrazol-5 -y l)pyridin-3 yl)methoxy)benzaldehyde |
55 | l-(2-formyl-3- hydroxyphenethyl)piperidine-4carboxylic acid |
In one group of embodiments, the compound is selected from:
2-(imidazo[I,2-a]pyridin-8-ylmethoxy)-5-methoxybenzaldehyde,
2-(imidazo[ 1,2-a]pyridin-2-ylmethoxy)-5-methoxybenzaldehyde,
2-(imidazo[l,5-a]pyridin-8-ylmethoxy)-5-methoxybenzaldehyde,
5-methoxy-2-(quinolin-5-ylmethoxy)benzaldehyde,
5-methoxy-2-(( 1 -methyl-1 H-indazol-4-yl)methoxy)benzaldehyde,
5-methoxy-2-((8-methylimidazo[l,2-a]pyridin-2-yl)methoxy)benzaldehyde,
2-((1 H-indazol-4-yl)methoxy)-5-methoxybenzaldehyde,
5 -methoxy-2-(pyridin-3 -ylmethoxy)benzaldehyde,
2-((2-(l-isopropyl-lH-pyrazol-5-yI)pyridin-3-yl)methoxy)-5-methoxybenzaldehyde, 2-hydroxy-6-((2-( 1 -isopropyl-1 H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde, 2-((3-(2H-tetrazol-5-yl)benzyl)oxy)-6-hydroxybenzaldehyde,
2-((4-(2H-tetrazol-5-yl)benzyl)oxy)-6-hydroxybenzaldehyde, methyl 4-((2-formylphenoxy)methyl)benzoate,
4-((2-formylphenoxy)methyl)benzoic acid, methyl 3 -((2-formylphenoxy)methyl)benzoate,
2-bromo-3-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde,
2-hydroxy-6-((2-(l-(2,2,2-trifluoroethyl)-lH-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde,
2-hydroxy-6-((2-( 1 -(3,3,3 -trifluoropropyl)-1 H-pyrazol-5-yl)pyridin-3 yl)methoxy)benzaldehyde,
2-fluoro-6-((2-(l-(2,2,2-trifluoroethyl)-lH-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde,
2-fluoro-6-((2-(l-(3,3,3-trifluoropropyl)-lH-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde,
2-fluoro-6-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde, and l-(2-formyl-3-hydroxyphenethyl)piperidine-4-carboxylic acid, or a tautomer or pharmaceutically acceptable sait thereof.
In one group of embodiments, provided is a compound in any of the Examples or Tables. In another group of embodiments, provided are any combinations of subembodiments as disclosed herein including any combination of éléments disclosed herein including the a sélection of any single éléments.
In one group of embodiments, provided is a pharmaceutical composition comprising a compound of any of the above embodiments or a tautomer or pharmaceutically acceptable sait thereof.
In one group of embodiments, provided is a pharmaceutical composition comprising a compound that is or a pharmaceutically acceptable sait thereof.
The compounds of the présent invention may be prepared by known organic synthesis techniques, including the methods described in more detail in the Examples.
In one group of embodiments, provided is an intermediate compound used in the préparation of the compounds disclosed herein.
In one group of embodiments, provided are methods for preparing the compounds disclosed herein. . .
For example, Scheme I shows a synthetic route for the synthesis of the compounds of Formula (I) where X is O and Y is CH2. Phénol 1.1 is contacted with intermediate 1.2 in the presence of base under ether forming conditions to give ether 1.3, where Lg represents a leaving group such as a halogen leaving group. Conversely, when X is O and Y is CH2, the compounds of Formula (I) can be prepared using the appropriate starting materials where the OH moiety of intermediate 1.1 is replaced with a leaving group and the Lg group of intermediate 1.2 is replaced with an OH group.
Scheme I
Scheme II shows an example of a synthetic route for the synthesis of the compounds of Formula (I) where X and Y are CH2. Alkene 2.1 is contacted with alkene 2.2 under metathesis forming conditions in the presence of an appropriate transition métal catalyst. Suitable catalysts include ruthénium catalysts such as Grubbs’ catalyst. Product 2.3 is then hydrogenated to give compound 2.4.
Scheme II
Scheme III shows an example of a synthetic route for the synthesis of the compounds of Formula (I) where R6 together with Rlb form a cyclic ether. Compound 3.1, is reacted with diethylphosphite and a base such as sodium methoxide to give intermediate 3.2, that is then condensed with aldéhyde 3.3 to give alkene 3.4. Treatment of the alkene with H2 under hydrogénation conditions gives lactone 3.4, which is then reduced with a suitable reducing agent such as LiBHEt3 to give cyclic hemiacetal 3.5.
Scheme III
Scheme IV shows an example of synthesis of the compounds of Formula (I) where Q is pyridine-3-yl and Ra heteroaryl. Acid 4.1 is reduced to alcohol 4.2 using known methods such as by forming the anhydride (e.g. treatment with triethylamine and Lbutyl chloroformate) followed by réduction with NaBH4. Alcohol 4.2 is converted to chloride 4.3 such as by treatment with thionyl chloride. Coupling of the halide with alcohol 4.4 under ether forming conditions gives the precursor 4.5 that can be functionalized with a variety to heteroaryl Ra groups. For example, 4.5 can be coupled with pyrazole 4.6 under known organometallic coupling conditions (e.g. Pd(PPh3)4 ) to give 4.7, where PG is a nitrogen protecting group such as a silyl protecting group that can be removed to give the product 4.8.
' ' 32 ‘
Scheme IV
One skilled in the art will recognize that in certain embodiments it may be advantageous to use a protecting group strategy. The protecting group can be removed using methods known to those skilled in the art.
In one group of embodiments, certain of the compounds disclosed herein may generally be utilized as the free base. Altematively, certain of the compounds may be used in the form of acid addition salts.
It is understood that in another group of embodiments, any of the above embodiments may also be combined with other embodiments listed herein, to form other embodiments of the invention. Similarly, it is understood that in other embodiments, listing of groups includes embodiments wherein one or more of the éléments of those groups is not included.
III. Compositions and Methods of Administration
Depending on the intended mode of administration, the pharmaceutical compositions may be in the form of solid, semi-solid or liquid dosage forms, preferably in unit dosage form suitable for single administration of a précisé dosage. In addition to an effective amount of the active compound(s), the compositions may contain suitable pharmaceutically-acceptable excipients, including adjuvants which facilitate processing of the active compounds into préparations which can be used pharmaceutically. “Pharmaceutically acceptable excipient” refers to an excipient or mixture of excipients which does not interfère with the effectiveness of the biological activity of the active compound(s) and which is not toxic or otherwise undesirable to the subject to which it is administered.
For solid compositions, conventional excipients include, for example, pharmaceutical grades of mannitol, lactose, starch, magnésium stéarate, sodium saccharin, talc, cellulose, glucose, sucrose, magnésium carbonate, and the like. Liquid pharmacologically administrable compositions can, for example, be prepared by dissolving, dispersing, etc., an active compound as described herein and optional pharmaceutical adjuvants in water or an aqueous excipient, such as, for example, water, saline, aqueous dextrose, and the like, to form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary excipients such as wettihg or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc.
' 33
For oral administration, the composition will generally take the form of a tablet or capsule, or it may be an aqueous or nonaqueous solution, suspension or syrup. Tablets and capsules are preferred oral administration forms. Tablets and capsules for oral use will generally include one or more commonly used excipients such as lactose and corn starch. Lubricating agents, such as magnésium stéarate, are also typically added. When liquid suspensions are used, the active agent may be combined with emulsifying and suspending excipients. If desired, flavoring, coloring and/or sweetening agents may be added as well. Other optional excipients for incorporation into an oral formulation include preservatives, suspending agents, thickening agents, and the like.
Injectable formulations can be prepared in conventional forms, either as liquid solutions.or suspensions, solid forms suitable for solubiïization or suspension in liquid prior to injection, or as émulsions or liposomal formulations. The stérile injectable formulation may also be a stérile injectable solution or a suspension in a nontoxic parenterally acceptable diluent or solvent. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonie sodium chloride solution. In addition, stérile, fixed oils, fatty esters or polyols are conventionally employed as solvents or suspending media.
The pharmaceutical compositions of this invention may also be formulated in lyophilized form for parentéral administration. Lyophilized formulations may be reconstituted by addition of water or other aqueous medium and then further diluted with a suitable diluent prior to use. The liquid formulation is generally a buffered, isotonie, aqueous solution. Examples of suitable diluents are isotonie saline solution, 5% dextrose in water, and buffered sodium or ammonium acetate solution. Pharmaceutically acceptable solid or liquid excipients may be added to enhance or stabilize the composition, or to facilitate préparation of the composition.
Typically, a pharmaceutical composition of the présent invention is packaged in a container with a label, or instructions, or both, indicating use of the pharmaceutical composition in the treatment of the indicated disease.
The pharmaceutical composition may additionally contain one or more other pharmacologically active agents in addition to a compound of this invention.
Dosage forms containing effective amounts of the modulators are within the bounds of routine expérimentation and within the scope of the invention. A therapeutically effective dose may vary depending upon the route of administration and dosage form. The représentative compound or compounds of the invention is a formulation that exhibits a high therapeutic index. The therapeutic index is the dose ratio between toxic and therapeutic effects which can be expressed as the ratio between LD50 and ED50· The LD50 is the dose léthal to 50% of the population and the ED50 is the dose therapeutically effective in 50% of the population. The LD50 and ED50 are determined by standard pharmaceutical procedures in animal cell cultures or experimental animais. It should be understood that a spécifie dosage and treatment regimen for any particular patient will dépend upon a variety of factors, including the activity of the spécifie compound employed, the âge, body weight, general health, sex and diet of the patient, and the time of administration, rate of excrétion, drug combination, judgment of the treating physician and severity of the particular disease being treated. The amount of active ingredient(s) will also dépend upon the particular compound and other therapeutic agent, if présent, in the composition.
IV. Methods
In one group of embodiments, provided is a method for increasing tissue oxygénation, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any of the above embodiments or a tautomer or pharmaceutically acceptable sait thereof.
In one group of embodiments, provided is a method for treating a condition associated with oxygen deficiency, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any of the above embodiments or a tautomer or pharmaceutically acceptable sait thereof.
In one group of embodiments, provided is a method for treating sickle cell disease, cancer, a pulmonary disorder, stroke, high altitude sickness, an ulcer, a pressure sore, Alzheimer’s disease, acute respiratory disease syndrome, and a wound, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any of the above embodiments or a tautomer or pharmaceutically acceptable sait thereof.
In one group of embodiments, provided is a method for increasing tissue oxygénation or for treating a condition associated with oxygen deficiency, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound Formula (II):
(H) or a tautomer or pharmaceutically acceptable sait thereof, ’ 35 wherein Q is selected from the group consisting of aryl, heteroaryl, and heterocycloalkyl, each optionally substituted with one to three Ra;
Y is O or CRlaRIb, where RIa is H or halo and Rlb is selected from the group consisting of H, halo, and OH;
X is selected from the group consisting of O, >CH(CH2)nR8, and C(R9)2 where n is 0 or 1, R8 is OH, and R9 is independently H or halo; or Y-X taken together is -NHC(O)- or C(O)NH-;
R2, R3, R4, and R5 are independently selected from the group consisting of hydrogen, halo, Rb, ORd, -O(CH2)zORd, -O(CH2)zNRdRd, OC(O)Re, SRd, CN, NO2, CO2Rd, CONRdRd, C(O)Rd, OC(O)NRdRd, NRdRd, NRdC(O)Re, NRdC(O)2Re, NRdC(O)NRdRd, S(O)Re, S(O)2Re, NRdS(O)2Re, S(O)2NRdRd, and N3, where z is 0,1, 2, 3, 4, 5, or 6; or R5 is -(CH2)PR5a where p is 0 or 1 and R33 is OH;
R6 and R7 together form oxo or an aldéhyde protecting group, or R6 together with Rlb, R8, or R5 forms a cyclic ether where one of RIb, R8, or R5a is O, R6 is a bond, and R7 is selected from the group consisting of OH, Ci.8alkoxy, and haloCi.«alkoxy;
each Ra is independently selected from the group consisting of halo, Rb, ORd, O(CH2)uORd, O(CH2)uNRdRd, O(CH2)uNRdC(O)Re, O(CH2)uNRdC(O)2Re, O(CH2)uNRdS(O)2Re, NH2, -(CH2)kOC(O)Re, -(CH2)kSRd, CN, NO2, -(CH2)kCO2(C1. 8alkyl)OH, -(CH2)kCO2(Ci.8alkyl)(heteroaryl)C(O)(Ci.8alkyl), -(CH2)kCO2Rd, -(CH2)kCONRdRd, -(CH2)kNRdC(O)Re. -(CH2)kNRdC(O)2Re, -(CH2)kC(O)Rd, -(CH2)kOC(O)NRdRd, -NRd(CH2)uORd, -NRd(CH2)uNRdRd, -NRd(CH2)uNRdC(O)Re, -NRd(CH2)uNRdC(O)2Re, -NRd(CH2)uNRdS(O)2Re, -(CH2)kNRdC(O)Re, -(CH2)kNRdC(O)2Rd, -(CH2)kNRdC(O)NRdRd, -(CH2)kS(O)Re, -(CH2)kS(O)2Re, -(CH2)kNRdS(O)2Re, -(CH2)kS(O)2NRdRd, N3, -(CH2)karyl optionally substituted with one to three Rc, -NRd(CH2)karyl optionally substituted with one to three Rc, -(CH2)kheteroaryl optionally substituted with one to three Rc, -NRd(CH2)kheteroaryl optionally substituted with one to three Rc, -(CH2)kheterocycloalkyl optionally substituted with one to three Rc, and -NRd(CH2)kheterocycloalkyl optionally substituted with one to three Rc where k is 0,1,2, 3, 4, 5, or 6 and u is 1,2, 3,4, 5, or 6;
each Rb is independently selected from the group consisting of Ci.8alkyl, C2.8alkenyl, and C2-8 alkynyl, each optionally independently substituted with one to three halo, ORd, or NRdRd;
Ύ9779 each R is independently selected from the group consisting of halo, C].8alkyl, haloC). «alkyl, C2-8alkenyl, haloC2.8 alkenyl, C2-8alkynyl, haloC2-8alkynyl, (CH2)mORf, OC(O)Rg, SR1, CN, NO2, CO2Rf, CONRfRf, C(O)Rf, OC(O)NRfRf, (CH2)mNRfRf, NRfC(O)Rg, NRfC(O)2Rg, NRfC(O)NRfRf, S(O)R8, S(O)2RS, NRfS(O)2Rs, S(O)2NRfRf, N3, heteroaryl optionally substituted with one to three Rh, and heterocycloalkyl optionally substituted with one to three Rh where m is selected from the group consisting of 0, 1, 2, 3, 4, 5, and 6;
Rd, Rf, and RJ are each independently selected from the group consisting of hydrogen, Ci-8 alkyl, haloCi.8alkyl, C2.8 alkenyl, haloC2.8alkenyl, C2.8 alkynyl, and haloC2.8alkynyl; and
Re, Rg, and R‘ are each independently selected from the group consisting of Ci-8alkyl, haloCi.8alkyl, C2.8 alkenyl, haIoC2.8alkenyl, C2.8 alkynyl, and haloC2.8alkynyl;
provided that X and Y are not both O;
provided that when X is O, Rlb is not OH;
provided that when Y is O, and n is 0, R8 is not OH; and provided that when R6 and R7 together are oxo, one R2, R3, R4, and R5 is methoxy or ethoxy, and the other of R2, R3, R4, and R5 is H, then Q is not unsubstituted pyridin-2-yl, pyridin-3-yl, or pyridin-4-yl.
In one group of embodiments, provided is a method wherein z is 0. In another group of embodiments, z is 1. embodiments, z is 3. embodiments, z is 5.
In yet another group of embodiments, z is 2. In still another group of
In another group of embodiments, z is 4. In yet another group of
In still another group of embodiments, z is 6.
V. Examples
The following examples are offered to illustrate, but not to limit, the claimed invention.
PREPARATIVE EXAMPLES
The starting materials and reagents used in preparing these compounds generally are either available from commercial suppliers, such as Aldrich Chemical Co., or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser’s Reagents for Organic Synthesis; Wiley & Sons: New York, 1967-2004, Volumes 1-22; Rodd’s Chemistry of Carbon Compounds, Elsevier Science Publishers, 1989,
Volumes l-5 and Supplémentais; and Organic Reactions, Wiley & Sons: New York, 2005, Volumes l-65.
The starting materials and the intermediates of the synthetic reaction schemes can be isolated and purified if desired using conventional techniques, including but not limited to, filtration, distillation, crystallization, chromatography, and the like. Such materials can be characterized using conventional means, including physical constants and spectral data.
Unless specified to the contrary, the reactions described herein preferably are conducted under an inert atmosphère at atmospheric pressure at a reaction température range of from about -78°C to about 150°C, more preferably from about 0°C to about 125°C, and most preferably and conveniently at about room (or ambient) température, e.g., about 20°C to about 75°C.
Referring to the examples that follow, compounds of the présent invention were synthesized using the methods described herein, or other methods known in the art.
Example 1. Préparation of 2-(imidazo[l,5-a]pyridin-8-ylmethoxy)-5-methoxybenzaldehyde
Step 1:
To a cold solution of 3-ethoxycarbonylpyridine (25 g, 165.4 mmol, 1 eq) in DCM was slowly added mCPBA (70% wt, 198.5 mmol) and the reaction mixture was stirred at rt ovemight.Reaction was cooled and diluted with DCM and then neutralized with slow addition of sat. NaHCO3.Aqueous layer was washed with DCM (3X) and the combined organic layer was dried and evaporated to give a residue, which was purified by column chromatography (EtOAc/ MeOH) to give 3-ethoxycarbonylpyridine N-oxide (13.6 g). MS: exact mass calculated for C8H9NO3, 167.06; m/z found, 168 [M+H]+.
Step 2:
To a solution of 3-ethoxycarbonylpyridine N-oxide in 330 mL of DCM were added trimethylsilyl cyanide (TMSCN) (11.0 g, 65.9 mmol, 1.0 eq) and dimethylcarbamoyl chloride (7.1 g, 65.9 mmol, 1.0 eq) and the reaction mixture was stirred at rt for 2 days. Then 10% K2CO3 was slowly added to make the reaction mixture basic.Organic layer was separated, dried and evaporated to provide the crude, which was purified by column chromatography to provide compounds A (5.7 g) and B (3.5 g).
Steps 3 and 4:
To a solution of ethyl 2-cyano-3-pyridinecarboxylate (2.5 g) and conc. HCl (5 mL) in 150 mL éthanol was added 10% Pd/C (wet, 250 mg) and the reaction mixture was hydrogenated using a hydrogen balloon and stirred for 12 h. The reaction was filtered through celite and éthanol was evaporated to give ethyl 2-(aminomethyl)-3-pyridinecarboxylate HCl as a white solid which was used in the next step without further purification.
A mixture of 44.8 mL of acetic anhydride and 19.2 mL of formic acid was heated in a 50-60 °C oil bath température for 3 h and then cooled to rt to give formic-acetic anhydride, which was then slowly added to the solid ethyl 2-(aminomethyl)-3-pyridinecarboxyIate HCl and then stirred at rt for 8 h. Excess reagent was evaporated to give a residue, which was neutralized by very slow addition of sat. NaHCO3 solution. Solution was extracted with DCM, dried and evaporated to provide ethyl imidazo[l,5-a]pyridine-8-carboxylate as a yellow solid (crude weight 2.7 g). MS: exact mass calculated for C10H10N2O2, 190.07; m/z found, 191 [M+H]+.
Steps 5 and 6:
To a cold solution of lithium aluminum hydride (1.62 g, 42,4 mmol, 4.0 eq) in THF (50 mL) was added the crude ethyl imidazo[l,5-a]pyridine-8-carboxylate (2.7 g, 14.2 mmol, 1.0 eq) and the reaction mixture was heated at reflux for 2 h. The reaction was cooled and water (1.7 mL), 15% NaOH (1.7 mL) and water (5.1 mL) were slowly added.Solution was diluted with excess EtOAc and stirred at rt for 30 min. The solution was filtered and the solid was washed with ethyl acetate. Organic layers were combined, dried and solvent was removed to give crude imidazo[l,5-a]pyridine-8-methanol, which was purified by column chromatography (EtOAc/ Hexane). MS: exact mass calculated for CgHg^O, 148.06; m/z found, 149 [M+H]
To a solution of imidazo[l,5-a]pyridine-8-methanol (800 mg) in chloroform (50 mL) was slowly added thionyl chloride (10 mL) and the reaction mixture was stirred at rt for 8 h. Chloroform was removed and the residue was then taken in toluene and toluene was evaporated (3x) to give a solid, which was used in the next step without further purification. MS: exact mass calculated for C8H7CIN2, 166.03; m/z found, 167 [M+H]+.
Step 7:
To a solution of chloride (1.25 mmol, 1.0 eq), and phénol (1.25 mmol, 1.0 eq) in DMF (10 mL) was added K2CO3 (3.0 eq) and the réaction mixture was heated at 80-90 °C for 5 h. ' Solvent was removed and the residue was purified by column chromatography (EtOAc/ MeOH).NMR (400 MHz, CDCI3): δ 3.82 (s, 3H), 5.45 (s, 2H), 6.58 (m, 1H), 6.81 (m, 1H), 7.03 (s, 1H), 7.12 (m, 1H), 7.35 (m, 1H), 7.50 (s, 1H), 7.95 (m, 1H), 8.18 (s, 1H), 10.58 (s, 1H); MS: exact mass calculated for C16H14N2O3,282.10; m/z found, 283 [M+H]+.
Example 2. Préparation of 2-(imidazo[l,5-a]pyridin-8-ylmethoxy)-4-methoxybenzaldehyde
The title compound was prepared using 2-hydroxy-4-methoxybenzaldehyde in a similar manner as in Example 1. NMR (400 MHz, CDCI3): δ 3.85 (s, 3H), 5.50 (s, 2H), 6.50-6.60 (m, 3H), 6.88 (s, 1H), 7.48 (s, 1H), 7.88 (m, 2H), 8.18 (s, 1H), 10.58 (s, 1H); MS: exact mass calculated for C16H14N2O3, 282.10; m/z found, 283 [M+H]+.
Example 3. Préparation of2-(imidazo[l,5-a]pyridin-6-ylmethoxy)-5-methoxybenzaldehyde
Steps 1 and 2:
To a solution of ethyl 6-cyano-3-pyridinecarboxylate (3.75 g) and conc. HCl (7.5 mL) in 225 mL éthanol was added 10% Pd/C (wet, 375 mg) and the reaction mixture was hydrogenated. using hydrogen balloon and stirred for 12 h. Solution was filtered through celite and éthanol was evaporated to give ethyl 6-(aminomethyl)-3-pyridinecarboxylate HCl as a white solid, which was used in the next step without further purification.
A mixture of 67.2 mL of acetic anhydride and 28.8 mL of formic acid was heated at 50-60 °C oil bath température for 3 h and then cooled to rt to give formic-acetic anhydride, which was then slowly added into the solid ethyl 2-(aminomethyl)-3-pyridinecarboxylate HCl and then stirred at rt for 8 h. Excess reagent was evaporated to give a residue, which was neutralized by very slow addition of sat NaHCÛ3 solution. Solution was extracted with DCM, dried and .
evaporated to provide imidazo[l,5-a]pyridine as a yellow solid.MS: exact mass calculated for C10H10N2O2, 190.07; m/z found, 191 [M+H]+.
Steps 3 and 4:
To a cold solution of lithium aluminum hydride (1.0 g, 26.3 mmol, 2.0 eq) in THF (40 mL) was added the crude ethyl imidazopyridine carboxylate (2.5 g, 13.2 mmol, 1.0 eq) and the réaction mixture was stirred at rt for 2 h. Reaction was cooled and water (1.7 mL), 15% NaOH (1.7 mL) and water (5.1 mL) were slowly added.Solution was next diluted with excess EtOAc and stirred at rt for 30 min. The solution was tiltered and the solid was washed with ethyl acetate. Organic layers were combined, dried and solvent was removed to give crude imidazo[l,5-a]pyridine-8-methanol, which was purified by column chromatography (EtOAc/ Hexane). MS: exact mass calculated for C8H8N2O,148.06; m/z found, 149 [M+H]+.
To a solution of imidazopyridine methanol (700 mg, 4.7 mmol, 1.0 eq) in chloroform (20 mL) was slowly added thionyl chloride (1.7 mL) and the reaction mixture was stirred at rt for 8 h. Chloroform was removed and the residue was then taken up in toluene. Toluene was evaporated (3x) to give a solid (550 mg), which was used in the next step without further purification.
Step 5:
To a solution of chloride (1.25 mmol, 1.0 eq), and phénol (1.25 mmol, 1.0 eq) in DMF (10 mL) was added K2CO3 (3.0 eq) and the reaction mixture was heated at 80-90 °C for 5 h. Solvent was removed and the residue was purified by column chromatography (EtOAc/ MeOH).MS: exact mass calculated for Ci6H]4N2O3,282.10; m/z found, 283 [M+H]+.
Example 4. Préparation of2-(imidazo[l,5-a]pyridin-6-ylmethoxy)-4-methoxybenzaldehyde
The title compound was prepared using 2-hydroxy-4-methoxybenzaldehyde in a similar manner as in Example 3.
Example 5. Préparation of methyl imidazo[l,2-a]pyridine-8-carboxylate .
' 41
To a solution of methyl 2-amino-pyridine-3-carboxylate (5 g, 35 mmol, 1.0 eq) in éthanol (250 mL) was added NaHCO3 (5.08 g) and chloroacetaldehyde in water (35 mL of 45% in water, 148 mmol, 4.5 eq). The reaction mixture was heated at reflux for 18 h. Solvent was removed and the residue was basified with Na3CO3 and then extracted with DCM. Organic layers were combined and evaporated to give a residue, which was purified by column to give the titled compound.
Example 6. Préparation of imidazo[l ,2-a]pyridin-8-ylmethanol
To a cold solution of methyl imidazo[l,2-a]pyridine-8-carboxylate e (5.55 g, 31.53 mmol, 1 eq) in THF (100 mL) was added LAHinether ( 1 M solution in ether, 4 equiv.) and then stirred at rt for 6 h. The reaction mixture was cooled to 0 °C and quenched with water/ 15% NaOH/ water. Reaction mixture was diluted with ethyl acetate and stirred at room température for 15 min and then filtered. The solid was washed with éthanol and the organic layers were combined, dried and evaporated to give the alcohol, which was purified by column chromatography to yield the desired product in 40% yield.
Example 7. Préparation of8-(chloromethyl)imidazo[l,2-a]pyridine
A mixture of imidazo[l,2-a]pyridin-8-ylmethanol (800 mg) and excess thionyl chloride was stirred at 70-80 °C for 8 h. Excess thionyl chloride was removed under vacuum. The residue was then diluted with tohiene and evaporated. This procedure was repeated 3 times.
Example 8. Préparation of2-(imidazo[l,2-a]pyridin-8-ylmethoxy)-5-methoxybenzaldehyde
To a solution of the crude 8-(chloromethyl)imidazo[l,2-a]pyridine (6.8 mmol, 1 eq) and 2hydroxy-5-methoxybenzaldehyde (1.3 g, 8.1 mmol, 1.2 eq) in DMF (20 mL) was added potassium carbonate (2.8 g, 20.4 mmol, 3 eq) and the reaction mixture was heated at 85-90 °C for 5 h. DMF was removed under vacuum and the residue was taken in ethyl acetate and filtered. The solid was washed with additional ethyl acetate, and then dried and evaporated to give the crude, which was purified by column chromatography (EtOAc/ Hexane) to yield the desired compound in 45% yield. NMR (400 MHz, CDC13): δ 3.80 (s, 3H), 5.60 (s, 2H), 6.85 (d, 1H), 7.12 (d, 2H), 7.36(m, 2H), 7.66 (m, 2H), 8.14 (m, 1H), 10.58 (s, 1H); MS: exact mass calculated for CiôHi4N2O3, 282.10; m/z found, 283 [M+H]+.
'
Example 9. Préparation of 2-(imidazo[l,2-a]pyridin~8-ylmethoxy)-4-methoxybenzaldehyde
The title compound was prepared using 2-hydroxy-4-methoxybenzaldehyde in a similar manner as in Example 3. NMR (400 MHz, CDCI3): δ 3.88 (s, 3H), 5.65 (s, 2H), 6.58 (m, 1H), 6.68 (s, 1H), 6.88 (m, 1H), 7.42 (m, 1H), 7.66 (m, 2H), 7.83 (m, 1H), 8.14 (m, 1H), 10.45 (s, 1H); MS: exact mass calculated for Ci6Hi4N2O3, 282.10; m/z found, 283 [M+H]L
Example 10. Préparation of5-methoxy-2-((l-methyl-lH-indazol-4-yl)methoxy)benzaldehyde (Compound 115)
Step 1:
To a mixture of l-methyl-lH-indazole-4-carbaldehyde (180 mg, 1.12 mol) in THF (10 mL) was added NaBH4 (85 mg, 2.24 mmol) at rt. The reaction mixture was stirred at rt for 1 h, acidified to pH 3, and extracted with EtOAc. The combined organic layer was washed with saturated sodium bicarbonate solution and brine, dried over Na2SO4, filtered, and concentrated to give a crude solid (191 mg), which was used for next step without further purification.
Step 2:
To (l-methyl-lH-indazol-4-yl)methanol (191 mg) in DCM ( 5 mL) was added SOC12 (2 mL) at rt. The reaction mixture was stirred at rt for 4 h and concentrated to dryness. The crude solid was suspended in toluene and concentrated to dryness. The process was repeated three times and dried under vacuum to give an off-white solid (210 mg), which was used for next step without further purification.
Step 3:
A mixture of 2-hydroxy-5-methoxybenzaldehyde (170 mg, 1.12 mmol), 4-(chloromethyl)-lmethyl-lH-indazole (1.12 mmol), and K2CO3 (618 mg, 4.48 mmol) was reflux in CH3CN (20 mL) for 2 h. The mixture was filtered and the solid was washed with DCM. The filtrate was concentrated and purified on silica gel using a mixture of EtOAc and MeOH as eluent to give ' 43 '
5-methoxy-2-((l-methyl-lH-indazol-4-yl)methoxy)benzaldehyde (215 mg, 81% forthree steps) as a white solid. 'H NMR (400 MHz; DMSO) δ- 10.39 (s, 1 H), 8.20 (d, 1 H), 7.63 (d, 1 H) 7.36-7.64 (m, 2 H), 7.23-7.29 (m, 2 H), 7.18 (d, 1 H). 5.58 (s, 2 H), 4.06 (s, 3 H), 3.34 (s, 3 H). LRMS (M+H+) m/z 297.1.
Example IL Préparation of 2-((1 H-indazol-4-yl)methoxy)-5-methoxybenzaldehyde
Step 1 :
To a mixture of 4-(chloromethyl)-lH-indazole (1.0 g, 6.0 mol) in DCM (20 mL) was added (Boc)2O (1.96 g, 9.0 mmol) and DMAP (dimethylamino pyridine 67.2 mg, 0.6 mmol) at rt. The reaction mixture was stirred at rt for 1 h, concentrated, and purified on silica gel to give tert-butyl 4-(chloromethyl)-lH-indazole-l-carboxylate (1.4 g, 88%) as an a colorless oil.
Step 2:
A mixture of 2-hydroxy-5-methoxybenzaldehyde (46 mg, 0.3 mmol), tert-butyl 4(chloromethyl)-lH-indazole-l-carboxylate (80 mg, 0.3 mmol), and K2CÛ3 (166 mg, 1.2 mmol) in DMF (1.0 mL) was heated at 80 °C for 2 h. The mixture was filtered and the solid was washed with DCM. The filtrate was concentrated and purified on silica gel using a mixture of EtOAc and hexanes as eluent to give tert-butyl 4-((2-formyl-4methoxyphenoxy)methyl)-lH-indazole-l-carboxylate (88 mg, 77%) as a colorless oil.
Step 3:
To tert-butyl 4-((2-formyl-4-methoxyphenoxy)methyl)-lH-indazole-l-carboxylate (88 mg, 0.23 mmol) in DCM (5.0 mL) was added TFA (2.0 mL). The mixture was stirred at rt for 2 h and concentrated. The crude was purified on silica gel using a mixture of EtOAc and hexanes as eluent to give 2-((1 H-indazol-4-yl)methoxy)-5-methoxybenzaldehyde (50 mg, 77%) as a white solid. !HNMR (400 MHz; CDC13) δ- 10.53 (s, 1 H), 8.23 (s, 1 H), 7.54 (d, 1 H) 7.43 (t, 1 H), 7.38 (d, 1 H), 7.25 (d, 1 H), 7.08-7.15 (m, 2 H), 5.51 (s, 2 H), 3.82 (s, 3 H). LRMS (M+H^ m/z 283.1.
Example 12. Préparation of3-(imidazo[l,2-a]pyridin-8-ylmethyl)-l,3 dihydroisobenzofuran-l-ol
Step 1:
To a solution of methyl imidazo[l,2-a]pyridine-8-carboxylate (1.76 g, 10 mmol) in toluene was added DIB AL (1M/THF, 20 ml) at -78 °C dropwise. The mixture was stirred at -78 °C for 1 h, quenched with MeOH (2 mL) and saturated NH4C1 solution (50 mL) and warmed up to rt. The mixture was continued to stir at rt for 1 h and diluted with DCM (60 mL). fhe aqueous layer was extracted with DCM (60 mL) twice. The combined organic layer was dried over MgSO4 and concentrate. The residue was purified on silica gel with 10 % MeOH/DCM to give imidazo[l,2-a]pyridine-8-carbaldehyde (0.8g, 55%). LRMS (Μ+γΓ) m/z 147.1.
Step 2:
To a solution of sodium methoxide (5.4 M, 4.8 rnL) in MeOH (20 mL) was added diethyl phosphite (3.31 g, 24 mmol) at 0 °C followed by addition of 2-formylbenzoic acid (3.0 g, 20 mmol) portion-wise over a period of 20 min. The resulting mixture was warmed up to rt and continued to stir for 2 h. Methanesulphonic acid (2.69 g, 28 mmol, 1.4 equiv.) was added to the above mixture over a period of 30 min. The reaction mixture was stirred for 30 min and concentrated to remove most of the MeOH. The residue was partitioned between DCM (100 mL) and water (50 mL). The aqueous layer was extracted DCM twice. The combined organic layer was dried over Na2SO4 and concentrated to give dimethyl 3-oxo-l,3dihydroisobenzofuran-l-ylphosphonate (4.6 g, 90%). LRMS (M+H+) m/z 257.1.
Step 3:
To a solution of dimethyl 3-oxo-l,3-dihydroisobenzofuran-l-ylphosphonate (610 mg, 2.4 mmol), imidazo[l,2-a]pyridine-8-carbaldehyde (350 mg, 2.4 mmol, 1 equiv.) in THF ( 5 mL) was added Et3N (0.33 mL 2.4 mmol). The mixture was stirred at rt for 48 h. The précipitation was filtered off and washed with EtOAc. The fîltrate was concentrated to give 3(imidazo[l,2-a]pyridin-8-ylmethylene)isobenzofuran-l(3H)-one(400 mg, 64%) as a yellow solid. Small crude sample (~20 mg ) was purificd on RP-HPLC with CH3CN and water as eluent to separated the E/Z isomers (10 mg, 7 mg). ’H NMR(400 MHz, CD3OD) Z-form: δ= 8.52 (d, 1 H), 7.95-7.91 (m, 2 H), 7.62-7.54 (m, 4 H), 7.52-7.48 (m, 1 H), 7.09 (s, 1 H), 7.04 (t, 1 H) E-form: δ= 8.38 (d, 1 H), 8.15 (d. H), 8.05 (d, 1 H), 7.95 (d, 1 H), 7.90-7.84 (m, 2 H), 7.67 (t, 1 H), 7.64 (s, 1 H), 7.33 (s, 1 H), δ 7.05 (t, 1 H). LRMS (M+H+) m/z 263.1
Step 4:
To a solution of 3-(imidazo[l,2-a]pyridin-8-ylmethylene)isobenzofuran-l(3H)-one (180 mg, 0.69 mmol) in EtOAc (12 mL) was added 10% Pd/C (110 mg). The mixture was stirred under a hydrogen balloon overnight. The catalyst was filtered off and the filtrate was concentraied and purified on silica gel with 10% MeOH/DCM as eluent to give 3-(imidazo[l,2-a]pyridin8-ylmethyl)isobenzofuran-l(3H)-one (140 mg, 78%). 'H NMR (400 MHz, CD3OD) δ= 8.37 (d, 1H), δ 7.88 (s, 1 H), 7.83 (d, 1 H), 7.74-7.63 (m, 2 H), 7.60-7.53 (m, 2 H), δ 7.22 (d,l H), 6.86 (t, 1 H), 6.04 (dd, 1 H), 3.76 (dd, 1 H), 3.24 (dd, 1 H). ). LRMS (M+H+) m/z 265.1
Step 5:
To a solution of 3-(imidazo[l,2-a]pyridin-8-ylmethyl)isobenzofuran-l(3H)-one (80 mg, 0.3 mmol) in DCM (6 mL) at -78 °C, was added lithium triethyl borohydride (1M/THF, 0.3 mL) dropwise. The reaction mixture was stirred at -78 °C for 30 min, diluted with DCM (\; 10 mL), and quenched with MeOH (1 mL) and 5% HCl (2 mL). The mixture was warmed up to rt and stirred for 1 h. The solvents were removed and the residue was purified on RP-HPLC using CH3CN and water as eluent to give 3-(imidazo[l,2-a]pyridin-8-ylmethyl)-l,3dihydroisobenzofuran-l-ol (20 mg, 25%). 'HNMR(400 MHz, CD3OD) δ= 8.56 (t, 1 H), 8.97(d, 1 H), 7.74 (s, 1 H), 7.45-7.32 (m, 5 H), 7.07-7.00 (m, 1H), 6.38-6.30 (m, 1 H), 5.845.80(m, 0.5 H), 5.56 (dd, 0.5 H), 3.69 (t, 0.5 H), 3.65 (t, 0.5 H), 3.26 (dd, 0.5 H), 3.13 (dd, 0.5 H). LRMS (M+H+) m/z 267.1.
Example 13. Préparation of5-(imidazo[l,2-a]pyridin-8-ylmethoxy)-2methoxyibenzaldehyde.
Step 1:
To a mixture of 6-methoxyphen-3-ol (25 g, 0.2 mol) and K2CO3 (82.8 g, 0.6 mol) in DMF (250 mL) is added bromomethyl methyl ether (30 g, 0.24 mmol) slowly at rt for a period of Ih. The reaction mixture is filtered and the filtrate is concentrated. The residue is purified on silica gel with 25% EtOAc/hexanesas eluent to give 2-methoxy-5(methoxymethoxy)benzene.
Step 2:
To a solution of 2-methoxy-5-(methoxymethoxy)benzene (20 g, 0.1 2 mol) in THF is added diisopiopylamine (0.24 g, 2.4 mmol). The solution is cooled to -40 °C followed by addition of MeLi (3M/THF, 72mL, 0.216 moi) slowly. The resulting mixture is wanned to 0 °C, stirred at 0 °C for 3 h. cooled back down to -40 °C and added N-formylpiperidine (24mL, 0.216rnol). After stirring at -40 °C for 2 h, the mixture is quenched with a mixed solution of HCI (37%, 120 mL) and THF (250 mL). The température is then raised to rt and diluted with water (200 mL) and EtOAc (200 mL). The pH of the mixture is adjusted to 8-9 with solid K2CO3 and extracted with EtOAc (300 mL) twice. The organic layer is combined, dried over Na2SO4, and concentrated. The residue is purified on silica gel with 25%EtOAc/hexanes as eluent to give 2-methoxy-5-(methoxymethoxy)benzaldehyde.
Step 3:
To a solution of 2-methoxy-5-(methoxymethoxy)benzaldehyde (10 g, 0.05 mol) in THF (100 mL) was added 3 N HCl (150 mL). The reaction was stirred at 50 °C for 30 min, cooled to rt, and diluted with water (100 mL). The mixture was neutralized to pH 7-8 and extracted with EtOAc (200 mL) three times. The organic layer was dried over Na2SÛ4 and concentrated to give 5-hydroxy-2-methoxybenzaldehyde.
Step 4:
A mixture of 5-hydroxy-2-methoxybenzaldehyde (723.6 mg, 4.7 mmol), 8-(chloromethyl)imidazol[l,2-a] pyridine (785 mg, 4.7 mmol), and K2CO3 (1.9 g, 14.1 mmol) in DMF (20 mL) was heatëd at microwave reactor at 125 °C for 15 min. The mixture was filtered and concentrated. The residue was purified on silica gel (50-100% EtOAc in hexanes) to give 5(imidazo[l,2-a]pyridin-8-ylmethoxy)-2-methoxybenzaldehyde.
The compounds Examples 14-16 were prepared according to the procedure described m Example 13.
Example 14. Préparation of 2-(imidazo[l,2-a]pyridin-2-ylmethoxy)-5-methoxybenzaldehyde (Compound 5.) 'H NMR (400 MHz, DMSO) δ 10.39 (s, 1H), 8.53 (d, J = 6.8 Hz, 1H), 8.06 (s, 1H), 7.54 (d, J = 9.1 Hz, 1H), 7.42 (d, J= 9.1 Hz, 1H), 7.29-7.22 (m, 2H), 7.17 (d, J = 3.3 Hz, 1H), 6.90 (t, J - 6.8 Hz, 1H), 5.35 (s, 2H), 3.76 (s, 3H). ·
Example 15. Préparation of 5-methoxy-2-(quinolin-5-ylmethoxy)benzaldehyde (Compound 10).
'H NMR (400 MHz, CDC13) δ 9.09 (s, 1H), 7.73 (dd, J= 4.0, 1.3 Hz, 1H), 7.19 (d, J= 8.4 Hz, 1H), 6.92 (d. J- 8.4 Hz, 1H), 6.48 (t, J= 8.4 Hz,, 1H), 6.40 (d, J - 6.9 Hz, 1H), 6.24 (dd, J = 8.5, 4.2 Hz, 1H), 6.10 (d, J= 2.6 Hz, 1H), 5.95 - 5.85 (m, 2H), 4.32 (s, 2H), 2.56 (s, 3H).
Example 16. Préparation of 5nnethoxy-2-((8-methylimidazo[l,2-a]pyridin-2yl)methoxy)benzaldehyde (Compound 24).
'H NMR (400 MHz, CD3CN) δ 10.32 (s, 1H), 8.01 (d, 6.8 Hz, 1H), 7.68 (s, 1H), 7.19 (d,
J= 9.0 Hz, 1H), 7.13 (d, J - 3.2 Hz, 1H), 7.08 (dd,./ = 9.0, 3.3 Hz, 1H), 6.90 (td, ./=6.8, 1.2 H 1H), 6.62 (t, J= 6.s Hz, 1H), 5.21 (s, 2H), 3.67 (s, 3H), 2.39 (s, 3H).
Example 17. Préparation of 2-hydroxy-6-((2-(l-isopropyl-1 H-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde (Compound 43).
A mixture of 2,6-dihydroxybenzaldehyde (1.96 g, 14.2 mmol, 2 eq.) and CS2CO3 (7.5 g, 21.3 mmol, 3 eq.) in DMF (180 mL) was stirred at rt for 30 min. To this mixture was added 3(chloromethyl)-2-(l-isopropyl-lH-pyrazol-5-yl)pyridine hydrochloride (1.93 g, 7.1 mmol, leq.) at rt. The mixture was continued to stir at rt O/N, filtered, concentrated and purified on silica gel using a mixture of EtOAc and hexanes as eluent to give 2-hydroxy-6-((2-(lisopropyl-lH-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (920 mg, 37%) as a pale yellowoil. 'HNMR(400 MHz, CDCI3) δ 11.96 (s, 1H), 10.40 (s, 1H), 8.77 (dd, J=4.8,1.5 Hz, 1H), 8.00 (d, J=7.8 Hz, 1H), 7.63 (d,J= 1.8 Hz, 1H), 7.49 - 7.34 (m, 2H), 6.59 (d,J= 8.5 Hz, 1H), 6.37 (d,J= 1.8 Hz, 1H), 6.29 (d, J= 8.2 Hz, 1H), 5.10 (s, 2H),4.67 (sep, J = 6.7 Hz, 1H), 1.50 (d, J= 6.6 Hz, 6H). LRMS (M+H+) m/z 338.1
Exemple 18. Préparation of2-hydroxy-6-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde (Compound 43).
A mixture of 2,6-dihydroxybenzaldehyde (1.58 g, 11.47 mmol, 2 eq.) and K2CO3 (2.4 g, 5 17.22 mmol, 3 eq.) in DMF (150 mL) was stirred at rt for 10 min. To this mixture was added
3-(chloromethyl)-2-(l-isopropyl-lH-pyrazol-5-yl)pyridine hydrochloride (1.56 g, 5.74 mmol, leq.) at rt. The mixture was heated at 50 °C for 2 h, filtered, concentrated and purified en silica gel using a mixture of EtOAc and hexanes as eluent to give 2-hydroxy-6-((2-(lisopropyl-lH-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (1.71 g, 88%) as a pale yellow solid. 'H NMR (400 MHz, CDC13) δ 11.96 (s, 1 H), 10.40 (s, 1H), 8.77 (dd, J= 4.8, 1.5 Hz, 1H), 8.00 (d, J = 7.8 Hz, 1H), 7.63 (d, J= 1.8 Hz, 1H), 7.49-7.34 (m, 2H), 6.59 (d, J = 8.5 Hz, 1H), 6.37 (d, J = 1.8 Hz, 1 H), 6.29 (d,.7= 8.2 Hz. 1 H), 5.10 (s, 2H), 4.67 (sep,./= 6.7 Hz, 1H), 1.50 (d, J= 6.6 Hz, 6H). LRMS (M+H+) m/z 338.1
Example 19. Préparation of 5-((2-(2H-tetrazol-5-yl)pyridin-3-yl)methoxy)-2- methoxybenzaldehyde.
Step 1 :
To a mixture of 5-((2-bromopyridin-3-yl)methoxy)-2-methoxybenzaldehyde (100 mg, 0.31 mmol, 1 equiv), Zn (CN)2 (71 mg, 0.62 mmol, 2.0 equiv), Pd(PPh3)4 (72 mg, 0.06 mmol. 0.2 20 equiv) in a 5 mL microwave tube is added DMF (2 mL). The mixture is heated 15 min at 125 °C in a microwave reactor. The solid is filtered off and the filtrate is concentrated to dryness.The crude was purified on silica gel using a mixture of EtOAc and hexanes as eluent to give 3-((4-formyl-6-methoxyphen-3-yloxy)methyl)picolinonitrile.
Step 2:
25;
· Το TEA hydrochloride sait (123 mg, 0.89 mmol, 4 equiv.) and 3-((4-formyl-6-methoxyphen3-yloxy)methyl)picolinonitrile (70 mg, 0.26 mmol, 1 equiv.) in chlorobenzene (5.0 mL) is added NaN3 (48 mg, 0.89 mmol, 4 equiv.) at rt. The mixture is heated to 110 °C for 2 h, cooled to rt, and added water (5.0 mL). The precipitate is filtered and washed with EtOAc 30 and water and dried under high vacuo to give 5-((2-(2H-tetrazol-5-yl)phen-3-yl)methoxy)-2methoxyisonicotinaldehyde.
The compounds in Examples 20 and 21 were prepared according to the procedure described in Example 19.
Example 20. Préparation of 2-((3-(2H-tetrazol-5-yl)benzyl)oxy)-6-hydroxybenzaldehyde (Compound 44).
’H NMR (400 MHz, CD3CN) 8 11.95 (s, 1H), 10.45 (s, 1H), 8.17 (s, 1H), 8.05 (d, 7.7 Hz,
1H), 7.69 (d, ./= 7.8 Hz, 1H), 7.62 (t, Ί.Ί Hz, 1H), 7.49 (t, J= 8.4 Hz, 1H), 6.62 (d, • 8.3 Hz, 1H), 6.54 (d, J= 8.5 Hz, 1H), 5.30 (s, 2H).· ·
Example 21. Préparation of 2-((4-(2H-ietrazol-5-yl)benzyl)oxy)-6-hydroxybenzaldehyde (Compound 45).
'H NMR (400 MHz, DMSO) δ 11.77 (s, 1H), 10.40 (s, 1H), 8.06 (d, J= 8.2 Hz.;2H). 7.69 (d, J= 8.0 Hz, 2H), 7.54 (t, J= 8.4 Hz, 1H), 6.73 (d, J= 8.4 Hz, 1H), 6.56 (d. J= 8.5 Hz, 1H), 5.33 (s, 2H).
Example 22. Préparation of 5-((4-formyl-6-methoxyphen-3-yloxy)methyl)nicotinic acid.
Step 1:
A mixture of 5-hydroxy-2-methoxybenzaldehyde (352 mg, 2.29 mmol, 1 eq.), methyl 5(chloromethyl)nicotinate hydrochloride (506 mg, 2.29 mmol, leq.), and K2CO3 (1.26 g, 9.16 mmol, 4 eq.) in DMF (8.0 mL) is heated at 60 °C for 3 h. The mixture is cooled and added into water (50 mL) dropwise. The precipitate is filtered, washed with water, and dried to give methyl 5-((4-formyl-6-methoxyphen-3-yloxy)methyl)nicotinate.
Step 2:
To 5-((4-formyl-6-methoxyphen-3-yloxy)methyl)nicotinate (96 mg, 0.32 mmol, 1 eq.) in a mixture of MeOH/THF (1/3, 8.0 mL) is added NaOH (3 N, 1.7 mL, 5.1 mmol, 16 eq.). The mixture is stirred at rt for 2 h, acidified to pH 3, extracted with EtOAc (3 x 20 mL). The combined organic layers are dried over Na2SÛ4 and concentrated to give 5-((4-formyl-6methoxypyridin-3-yloxy)methyl)nicotinic acid. .
The compounds in Examples 23-25 were prepared according to the procedure described in Example 22.
Example 23. Préparation of methyl 4-((2-formylphenoxy)methyl)benzoate (Compound 46).
*HNMR(400 MHz, CDC13) δ 10.51 (s, 1 H), 8.01 (d,J=8.3 Hz, 211), 7.81 (dd, J =1.1, 1.8 Hz, 1H), 7.51-7.40 (m, 3H), 7.00 (t, J = 7.5 Hz, 1H), 6.94 (d, J = 8.4 Hz, 1H), 5.19 (s, 2H), 3.86 (s, 3H).
Example 24. Préparation of 4-((2-formylphenoxy)methyl)benzoic acid (Compound 47).
'HNMR (400 MHz, CDC13) δ 10.52 (s, 1H), 8.09 (d, J= 8.2 Hz, 2H), 7.81 (dd, J= 7.7, 1.6 Hz, 1H), 7.53 - 7.43 (m, 3H), 7.01 (t, J= 7.5 Hz, 1H), 6.95 (d, J = 8.4 Hz, 1H), 5.21 (s, 2H).
Example 25. Préparation of methyl 3-((2-formylphenoxy)methyl)benzoate (Compound 48).
'H NMR (400 MHz, CDC13) δ 10.58 (s. 1H), 8.14 (s, 1H), 8.06 (d, ./=7.8 Hz, 1H), 7.90 (dd, J-1.1,1.8 Hz, 1H), 7.69 (d, J =7.7 Hz, 1 H), 7.60-7.48 (m, 2H), 7.08 (dd,J= 14.4, 7.9 Hz, 2H). 5.26 (s, 2H), 3.96 (s, 3H).
Example 26. Préparation of 5-hydroxy-2-methoxybenzaldehyde.
Step 1:
To a solution of 6-methoxyphen-3-ol (20 g, 0.16 mol, 1 eq.) in DMF (200 mL) was added NaH (60% in minerai oil; 9.6 g, 0.24 mol, 1.5 eq.) at 0-5 °C portion-wise. Upon the completion of addition, the mixture was continued to stir at 0-5 °C for 15 min. added chloromethyl methyl ether (15.5 g, 0.19 mol, 1.2 eq.), stirred at 0-5 °C for another 20 min, and quenched with NH4Cl(Sat.) solution. The aqueous layer was extracted with EtOAc (3 x 100 mL) and the combined organic layers were washed with water and brine, dried over Na2SO4, concentrated , and purified on silica gel using 25% EtOAc/hexanes as eluent to give 2-methoxy-5-(methoxymethoxy)benzene (24.1 g, 89.3%) as a colorless oil.
Step 2:
To a mixture of 2-methoxy-5-(methoxymethoxy)benzene (30 g, 0.178 mol, 1 eq.) and diisopropylamine (507 uL, 3.6 mmol, 0.02 eq.) in THF (500 mL) was added methyl lithium (1.6 M/THF, 200 mL, 0.32 mol, 1.8 eq.) at -40 “C.Upon the completion of addition, the mixture was warmed to 0 °C, continued to stir at 0 °C for 3 h, cooled back down to -40 °C and added DMF (24.7 mL, 0.32 mol, 1.8 eq.) slowly. The mixture was then stirred at -40 °C for 1 h, quenched with a mixture of HCl (12 N, 120 mL) and THF (280 mL), warmed to rt, and added water (200 mL). The pH of the mixture was adjusted to pH 8-9 with solid K2CO3. ’ 51 '
The aqueous layer was extracted with EtOAc (300 mL) twice. The combined organic layers were dried over Na2SÜ4 and concentrated to give 2-methoxy-5(methoxymethoxy)benzaldehyde (33.5 g, 95.7%) as a brown solid, which was used for next step without further purification. 'H NMR (400 MHz; CD3OD) 7.90 (s, 1 H), 6.92 (s, 1 H), 5.64 (s, 1 H), 5.20 (s, 2 H), 3.84 (s, 3 H), 3.48 (s, 3 H). LRMS (M+H+) m/z 198.1
Step 3:
To a solution of 2-methoxy-5-(methoxymethoxy)benzaldehydc (33.5 g, 0.17 mol, 1 eq.) in THF (150 mL) was added HCl (3 N, 250 mL, 4.4 eq.). The reaction was stirred at 50 °C for 1 h, cooled to rt, and diluted with water (500 mL). The mixture was neutralized to pH 7-8 with solid K2CO3. The pale yellow solid was collected, washed with water, and dried to give 5hydroxy-2-methoxybenzaldehyde (17.9 g, 74.6%) as a pale yellow solid. 'H NMR (400 MHz; DMSO) δ= 10.31 (s, 1 H), 8.03 (s, 1 H), 6.89 (s, 1 H), 3.80 (s, 3 H). LRMS (M+H+) m/z 154.0.
Example 27. Préparation of 5-((2-(1-isopropyl-lH-pyrazol-5-yl)pyridin-3-yl)methoxy)-2methoxybenzaldehyde (Compound 150).
Step 1: .
To a solution of 2-bromonicotinic acid (4.0 g, 20 mrnol) and triethylamine (3.34 mL, 24 mmol, 1.2 eq.) in THF (100 mL) was added Lbutyl chloroformate (3.12 mL, 24 mmol, 1.2 eq.) at 0 °C. The mixture was stirred at 0 °C for 10 min and filtered. To this filtrate was added a suspension of NaBH4 (1.52 g, 40 mmol, 2 eq.) in water (1.0 mL) at 0 °C. The mixture was stirred for 30 min, added water (3 mL), continued to stir for 2 h, and concentrated to dryness. The crude was purified on silica gel using a mixture of ethylacetate and hexanes as eluent to give (2-bromopyridin-3-yl)methanol (3.4 g, 90%) as a white solid. LRMS (M+H+) m/z 188.0.
Step 2
To a mixture of (2-bromopyridin-3-yl)methanol (20.0 g, 106.4 mmol, 1 eq.) and imidazole (14.5 g, 212.8 mmol, 2 eq.) in DMF (50.0 mL) was added TBSC1 (19.2 g, 150.7 mmol, 1.2 eq.) at rt. The mixture was stirred at rt for 1 h and diluted with a mixture of water (100 mL) ' 52 and EtOAc (300 mL). The organic layer was washed with ΝΗ4Ο(5κι.) solution and brine, dried over Na2SO4, concentrated. and purified on silica gel using 10% EtOAc/hexanes as eluent to give 2-bromo-3-((tert-butyldimethylsilyloxy)methyl)pyridine (30.1 g, 94%) as a colorless oil. LRMS (M+H+) m/z 302.0.
Step 3
A mixture of 2-bromo-3-((tert-butyldimethylsilyloxy)methyl)pyridine (30.1 g, 100.0 mmol, 1 eq.) and Zn(CN)2 ( 23.5 g, 200.0 mmol, 2.0 eq.) in DMF (100.0 mL) was purged with N2 for 5 min and added Pd(PPh3)4 (5.78 g. 5.0 mmol, 0.05 eq.). The mixture was heated at 120 °C for 2 h under N2, cooled, filtered, concentrated, and purified on silica gel using a mixture of EtOAc and hexanes as eluent to give 3-((tert-butyldimethylsilyloxy)methyl)picolinonitrile (20.4 g, 82%) as a colorless oil. LRMS (M+H+) m/z 249.1.
Step 4:
Méthylmagnésium bromide (3M/ether, 41.0 mL, 123.4 mmol) was added to a stirred solution of 3-((tert-butyldimethylsilyloxy)methyl)picolinonitrile (20.4 g, 82.25 mmol) in THF (100.0 mL) at -78 °C. The reaction mixture was warm to rt, quenched with aqueous citric acid solution, and extracted with EtOAc (50 mL) twice. The combined organic layers were washed with NaHCO3 (Sat) solution and brine, dried over Na2SO4, concentrated, and purified on silica gel using a mixture of EtOAc/hexanes as eluent to give l-(3-((tertbutyldimethylsilyloxy)methyl)pyridin-2-yl)ethanone (12.9 g, 59%) as a colorless oil. LRMS (M+H+) m/z 266.2.
Step 5:
l-(3-((tert-butyldimethylsilyloxy)methyl)pyridin-2-yl)ethanone (10.8 g, 40.75 mmol) in dimethoxy-N,N-dimethylmethanamine (15.0 mL) was heated to reflux for 3 days. The mixture was concentrated and used for next step without further purification. LRMS (M+H+) m/z 321.1.
Step 6:
' 53
..... -.-—· - — — -- 19779
To f£)-l-(3-((tert-butyldimethylsilyloxy)methyl)pyridin-2-yl)-3-(dimethylamino)prop-2-enΐ-one (crude, 1.03 g, 3.22 mmol, l eq.) in EtOH (10 mL) was added isopropylhydrazine hydrochloride (430 mg, 3.86 mmol, 1.2 eq.). The mixture was heated at 80 °C for 2 h, cooled, added HCl (6 N, 0.5 mL). and stirred O/N. The mixture was concentrated and diluted 5 with EtOAc (80 mL) and NaHCO3(sat) ( 10 mL) solution. The layers were separated and the aqueous layer was extracted with EtOAc three times. The combined organic layers were dried over Na2SO4, concentrated, and purified on silica gel using EtOAc as eluent to give (2(l-isopropyl-lH-pyrazol-5-yl)pyridin-3-yl)methanol (500 mg, 71%) and (2-(l-isopropyl-lH- • pyrazol-3-yl)pyridin-5-yl)methanol (55 mg, 25%) as pale yellow oiE. Data for 2-(i10 isopropyl-lH-pyrazol-5-yl)pyridin-3-yl)methanol: *H NMR (400 MHz, CDCI3) δ 8.67 (dd, J
- 4.7, 1.5 Hz, 1H), 8.0 (d, J= 7.8 Hz. 1H), 7.61 (d, J= 1.8 Hz, 1H), 7.39 (dd, J= 7.8,4.8 Hz, 1H). 6.37 (d, J= 1.8 Hz, 1H), 4.67 (s, 2H), 4.55 (sep, J= 6.6 Hz 1H), 1.98-2.05 (br, 1H), 1.47 (d, ./ = 6.6 Hz, 6H). LRMS (M+H+) m/z 218.1 Data for (2-(l-isopropyl-lH-pyrazol-3yl)pyridin-5-yl)methanol: *H NMR (400 MHz, CDCI3) δ 8.62 (dd, J= 4.8, 1.6 Hz, IH), 7.72 15 (d, J =7.6 Hz, 1 H), 7.55 (d, J =2.4 Hz, 1 H), 7.23 (dd, J = 7.6, 4.8 Hz, 1H), 6.99 (dd, J= 8.0,
6.5 Hz, 1H), 6.07 (t, J= 7.6 Hz, 1H), 4.67 (d, J= 7.6 Hz, 2H), 4.58 (sep, J= 6.7 Hz. 1H), 1.60 (d, J= 6.7 Hz, 1H). LRMS (M+H+) m/z 218.1.
Step 7:
To (2-(l-iospropyl-lH-pyrazol-5-yl)pyridin-3-yl)methanol (560 mg. 2.58 mmol) in DCM ( 10 mL) was added SOC12 (3.0 mL) at rt. The reaction mixture was stirred at rt for 4 h and concentrated to dryness. The crude solid was suspended in toluene and concentrated to dryness. The process was repeated three times and dried under vacuum to give 3(chloromethyl)-2-(l-isopropyl-lH-pyrazol-5-yl)pyridine hydrochloride (700 mg) as an off25 white solid, which was used for next step without further purification.
Step 8: 1
A mixture of 5-hydroxy-2-methoxybenzaldehyde (395 mg, 2.58 mmol, 1 eq.), 3(chloromethyl)-2-(l-isopropyl-l H-pyrazol-5-yl)pyridine hydrochloride (700 mg, 2.58 mmol, 30 1 eq.), and K2CO3 (1.4 g, 10.32 mmol, 4 eq.) in DMF (10.0 mL) was heated at 70 °C for 2 h.
The mixture was cooled, filtered, concentrated, and purified on silica gel using a mixture of EtOAc and hexanes as eluent to give 5-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3yl)methoxy)-2-methoxybenzaldehyde (590 mg, 65%) as an off-white solid.
’ 54
Step 9:
5-((2-( l-isopropyl-lH-pyrazol-5-yl)pyridin-3-yl)methoxy)-2-methoxybenzaldehyde (980 mg. 2.78 mmol, 1 eq.) in HCl (6 N, 9.2 mL, 20 eq.) solution was frozen at -78 °C. The mixture was lyophilized O/N to give 5-((2-( 1-isopropyl-lH-pyrazol-5-yl)pyridin-3-yl)methoxy)-2methoxybenzaldehyde as a yellow solid.
Example 28. Préparation of 2-bromo-3-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3yl)melhoxy)benzaldehyde (Compound 49).
The title compound was prepared according to the procedure described in Example 27.
*H NMR (400 MHz, CDC13) δ 10.46 (s, 2H), 8.77 (d, .7- 4.6 Hz, 2H), 8.22 (d, J= 7.9 Hz, 2H), 7.64 (s, 2H), 7.59 (d, J= 7.8 Hz, 2H), 7.47 (dd, J= 8.0, 4.8 Hz, 2H), 7.37 (t, .7= 7.9 Hz, 2H), 7.04 (d, J = 8.1 Hz, 2H), 6.43 (d, J- 1.0 Hz, 2H), 5.11 (s, 4H), 4.67 (sep. J- 6.6 Hz, 3H), 1.50 (d, .7=6.6 Hz, 11 H).
Example 29. Préparation of2-hydroxy-6-((2-(l-(2,2,2-trifluorocthyl)-lH-pyrazol-5yl)pyridin-3-yl)methoxy)benzaldehyde (Compound 50).
Step 1:
To (3,3,3-trifluoroethyl)hydrazine (25 g, 50% wt in water,153.5 mmol, 1 eq.) in a RB flask (250 mL) was added HCl (12 N, 25.6 mL, 307.0 mmol, 2 eq.). The mixture was concentrated to give (3,3,3-trifluoroethyl)hydrazine dihydrochloride (1.07 g) as a yellow solid. LRMS (M+H) m/z 129.1.
Step 2:
To ('E)-l-(3-((tert-butyldimethylsily!oxy)methyl)pyridin-2-yl)-3-(dimethylamino)prop-2-en1-one (crude above, 5.91 g, 18.44 mmol, 1 eq.) in EtOH (20 mL) was added (3,3,3trifluoroethyl)hydrazine dihydrochloride (4.13 g, crude above, 22.13 mmol, 1.2 eq.) at rt. The mixture was heated at 80 °C for 1 h, concentrated, and diluted with EtOAc (50 mL) and NaHCO3(Sat) solution (10 mL). The layers were separated and aqueous layer was extracted with EtOAc three times. The combined organic layers were dried over Na2SO4, concentrated, and purified on silica gel using a mixture of EtOAc and hexanes as eluent to give 3-((tert
55--.
butyldimethylsilyloxy)methyl)-2-(l-(3,3,3-trifluoroethyl)-lH-pyrazol-5-yl)pyridine (5.90 g; 86% for 2 steps). LRMS (M+H+) m/z 372.2.
Step 3:
To 3-((tert-butyldimethylsily!oxy)methyl)-2-(l -(3,3,3-trifluoroethyl)-lH-pyrazol-5yl)pyridine (5.91 g, 15.93 mmol) in MeOH (20 mL) was added HCl (4 N, 8.0 mL). The mixture was stirred at rt for 1 h, concentrated, and diluted with EtOAc (50 mL) and NaHCO3(sat) solution (10 mL). The layers were separated and aqueous layer was extracted with EtOAc three times. The combined organic layers were dried overNaiSO j, and concentrated to give (2-(1-(3,3.3-trifluôroethyl)-lH-pyrazol-5-yl)pyridin-3-yl)methcnol (4.1 ' g, quantitative yield) as colorless oil. *H NMR (400 MHz, CDCI3) δ 8.54 (dd, ./=4.7, 1.5 Hz, 1H), 7.92 (dd, J=7.9, 1.2 Hz, 1 H), 7.57 (d, J = 1.9 Hz, 1 H), 7.30 (dd, J = 7.8,4.8 Hz, 1H), 6.50 (d, J= 1.9 Hz, 1H), 5.09 (q, J= 8.6 Hz, 2H), 4.63 (s, 2H), 1.76 (s, 1H). LRMS (M+H+) m/z 272.1
Step 4:
To (2-(l-(2,2,2-trifluoroethyl)-lH-pyrazol-5-yl)pyridin-3-yl)methanol (408 mg, 1.59 mmol) in DCM ( 5 mL) was added SOC12 (1.5 mL) at rt. The reaction mixture was stirred at rt for 4 h and concentrated to dryness. The crude solid was suspended in toluene and concentrated to dryness. The process was repeated three times and dried under vacuum to give 3(chloromethyl)-2-(l-(2,2,2-trifluoroethyl)-lH-pyrazol-5-yl)pyridine hydrochloride (498 mg) as an off-white solid, which was used for next step without further purification.
Step 5:
A mixture of 2,6-dihydroxybenzaldehyde (438 mg, 11.47 mmol, 2 eq.) and K2CO3 (2.4 g, 17.22 mmol, 3 eq.) in DMF (150 mL) was stirred at rt for 10 min. To this mixture was added 3-(chloromethyl)-2-(l-(2,2,2-trifluoroethyl)-lH-pyrazol-5-yl)pyridine hydrochloride (498 mg, 1.59 mmol, leq.) at rt. The mixture was heated at 50 °C for 2 h, filtered, concentrated and purified on silica gel using a mixture of EtOAc and hexanes as eluent to 2-hydroxy-6-((230 (1-(2,2,2-trifluoroethyl)-lH-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (338.4 mg,
56%) as a pale yellow solid. ’H NMR (400 MHz, CDCI3) δ 11.99 (s, 1H), 10.41 (s, 1H), 8.76 (dd, J = 4.7, 1.6 Hz, 1H), 8.01 (dd, J= 7.9, 1.4 Hz, IH). 7.69 (d, J- 1.9 Hz, 1H), 7.49 - 7.39 (m, 2H), 6.61 (d, J = 8.5 Hz, 1H), 6.53 (d, J = 1.9 Hz, 111), 6.32 (d, J= 8.3 Hz, 1H), 5.30 (q, J = 8.6 Hz, 2H), 5.17 (s, 2H). LRMS (M+H+) m/z 378.1
Example 30. Préparation of 2-hydroxy-6-((2-(l-(3,3,3-trijluoropropyl)-lH-pyrazol-5yl)pyridin-3-yl)methoxy)benzaldehyde (Compound 51).
Step 1:
To a mixture of benzyl hydrazinecarboxylate (5.0 g, 30.3 mmol, 1 eq.) and DIEA (15.0 mL, 90.9 mmol, 3 eq.) in DMF (20 mL) was added 3,3,3-trifluoropropyl bromide (10.7 g 60.6 ’ mmol, 2 eq.) at rt. The mixture was heated at 80 °C for 20 h, concentrated, and purified on silica gel using a mixture of EtOAc and hexanes as eluent to benzyl 2-(3,3,3trifluoropropyl)hydrazinecarboxylate (4.2 g; 53%) as a white solid. 'H NMR (400 MHz, CDC13) δ 7.33 - 7.17 (m, 5H), 6.11 (s, 1H), 5.01 (s, 2H), 4.00 (s, 1H), 3.00 (dd, J= 12.2, 7.1 Hz, 2H), 2.17 (qt, J= 10.8, 7.3 Hz, 2H). LRMS (M+H+) m/z 263.1
Step 2: .
To benzyl 2-(3,3,3-trifluoropropyl)hydrazinecarboxylate (1.7 g, 6.49 mmol, 1 eq.) in a mixture of EtOH (30 mL) were added Pd/C (1.0 g) and HCl (12 N, 2.0 mL). The mixture was charged with H2 (60 psi), stirred at rt for 1 h, filtered, and concentrated to give (3,3,3trifluoropropyl)hydrazine dihydrochloride (1.07 g) as a yellow solid. LRMS (M+H) m/z 129.1.
Step 3:
To (E)-l-(3-((tert-butyldimethylsilyloxy)methyl)pyridin-2-yl)-3-(dimethylamino)prop-2-en1-one (crude above, 1.73 g, 5.41 mmol, 1 eq.) in EtOFI (10 mL) was added (3,3,3trifluoropropyl)hydrazine dihydrochloride (1.30 g, crude above, 6.49 mmol, 1.2 eq.) at rt. The mixture was heated at 80 °C for 1 h, concentrated, and diluted with EtOAc (50 mL) and NaHCO3(Sat) solution (10 mL). The layers were separated and aqueous layer was extracted with EtOAc three times. The combined organic layers were dried over Na2SO4, concentrated, and purified on silica gel using a mixture of EtOAc and hexanes as eluent to give 3-((tertbutyldimethylsilyloxy)methyl)-2-(l-(3,3,3-trifluoropropyl)-lH-pyrazol-5-yl)pyridine ( 1.58 ™ — 19779 g; 76% for 2 steps). 'H NMR (400 MHz. CDCl3) δ 8.53 (dd, 4.7, l .6 Hz, l H), 7.96 - 7.88 (m, 1 H), 7.51 (d,J = 1.9 Hz, 1 H), 7.29 (dd, J = 7.9, 4.7 Hz, 1 H), 6.34 (d, .7= 1.9 Hz. 1H). 4.62 (s, 2H), 4.45 - 4.33 (m, 2H), 2.82 - 2.61 (m, 2H), 0.85 (s, 8H), -0.00 (s, 5H). LRMS (M+H+) m/z 386.2.
Step 4:
To 3-((tert-butyldimethyIsilyloxy)methyl)-2-(l-(3,3,3-trifIuoropropyl)-lH-pyrazol-5yl)pyridine (1.58 g, 4.1 mmol) in MeOH (20 mL) was added HCl (4 N, 4.0 mL). The mixture was stirred at rt for 1 h, concentrated, and diluted with EtOAc (50 mL) and NaHCO3(sat) solution (10 mL). The layers were separated and aqueous layer was extracted with EtOAc three times. The combined organic layers were dried over Na2SO4, and concentrated to give (2-(1-(3.3,3-trifluoropropyl)-lH-pyrazol-5-yl)pyridin-3-yl)methanol (1.1 g, 99%) as colorless oil. 'H NMR (400 MHz, CDC13) δ 8.64 (dd,./=4.7,1.7 Hz, 1H), 8.00 (dd, J= 7.9,1.7 Hz. 1H), 7.57 (d, J = 1.9 Hz, 1H), 7.38 (dd, J= 7.9,4.8 Hz, 1H), 6.48 (d, J= 1.9 Hz, 1H), 4.69 (s, 15 2H), 4.51 - 4.43 (m, 2H), 2.85 - 2.72 (m, 2H), 2.70 (s, 1H). LRMS (M+H+) m/z 272.1.
Step 5:
To (2-(l-(2,2,2-trifluoropropyl)-lH-pyrazol-5-yl)pyridin-3-yl)methanol (140 mg, 0.52 mmol) in DCM ( 5 mL) was added SOC12 (2.0 mL) at rt. The réaction mixture was stirred at rt for 4 20 h and concentrated to dryness. The crude solid was suspended in toluene and concentrated to dryness. The process was repeated three times and dried under vacuum to give 3(chloromethyl)-2-(l-(2,2,2-trifluoropropyl)-lH-pyrazol-5-yl)pyridine hydrochloride (498 mg) as an off-white solid, which was used for next step without further purification.
Step 6:
.25
A mixture of 2,6-dihydroxybenzaldehyde (144 mg, 1.04 mmol, 2 eq.) and K2CO3 (214 mg, 1.56 mmol, 3 eq.) in DMF (20 mL) was stirred at rt for 10 min. To this mixture was added 3(chloromethyl)-2-(l-(2,2,2-trifluoropropyl)-lH-pyrazol-5-yl)pyridine hydrochloride (168 mg, 0.52 mmol, leq.) at rt. The mixture was heated at 50 °C for 2 h, filtered, concentrated and on 30 RP-HPLC (Gemini 21.2 x 150 mm) using a mixture of CH3CN and water as eluent to give 2hydroxy-6-((2-(l-(3,3,3-trifluoropropyl)-lH-pyrazol-5-yl)pyridin-3...... 58
-- ·-— 19779 yl)methoxy)benzaldehyde (53.5 mg, 26%) as an off-white solid. 'H NMR (400 MHz, CDCL) δ 11,98 (s, 1H), 10.38 (s, 1H), 8.77 (dd, .7 =4.7,1.6 Hz, 1H), 8.01 (dd,J=7.9,1.6Hz. 1H), 7.61 (d, J= 1.9 Hz. 1H), 7.49-7.39(m, 2H), 6.61 (d,./=8.5 Hz, IH), 6.44 (d,J= 1.9 Hz, 1H), 6.34 (d, J= 8.2 Hz, 1H), 5.15 (s, 2H), 4.56 (dd, ./= 8.3. 6.7 Hz. 2H), 3.02 - 2.72 (in, 5 2H). LRMS (M+H+) m/z 392.1.
Example 31. Préparation of Benzaldehyde Dérivatives.
Compounds 52-55 were prepared according to the methods described above. · ·
2-FIuoro-6-((2-( 1 -(2,2,2-trifluoroethyl)-1 H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (Compound 52). 'H NMR (400 MHz, CDC13) δ 10.51 (s, 1 H), 8.74 (dd, J =4.7,1.6 Hz, 1H).
10. 8.21 (dd,J=7.9, 1.6 Hz, 1H), 7.70 (d, J- 1.9 Hz, 1H). 7.54 - 7.41 (m, 2H), 6.82 (dd,.7 = 10.0,8.6 Hz, 1H), 6.70 (d, J =8.5 Hz, 1H), 6.56 (d, J = 1.9 Hz, 1 H), 5.28 (q,J=8.6 Hz. 2H), 5.20 (s, 2H).
2-Fluoro-6-((2-(l-(3,3,3-trifluoropropyl)-lH-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde (Compound 53).'H NMR (400 MHz, CDCI3) δ 10.50 (s. 1H), 8.75 15 (dd, .7=4.7, 1.6 Hz, 1H), 8.22 (dd, J = 7.9, 1.6 Hz, 1H), 7.62 (d, J= 1.9 Hz, 1 H), 7.54-7.42 (m, 2H), 6.83 (dd, J= 10.0, 8.7 Hz, 1H), 6.73 (d, J= 8.5 Hz, 1H), 6.46 (d. J= 1.9 Hz. 1H), 5.19 (s, 2H), 4.59 - 4.51 (m, 2H), 2.96 - 2.76 (m, 2H).
2-Fluoro-6-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (Compound 54). 'H NMR (400 MHz, CDCI3) δ 10.41 (s, 1H), 8.66 (dd, J= 4.7. 1.6 Hz, 1H). 20 8.13 (dd.J=7.9,1.4 Hz, 1 H), 7.55 (d, J= 1.8 Hz, 1 H), 7.46-7.29 (m, 2H), 6.72 (dd. .7=
10.0,8.7 Hz, 1H), 6.59 (d, .7= 8.5 Hz, 1H), 6.29 (d,J= 1.8 Hz, 1H), 5.03 (s, 2H), 4.56 (sep, J = 6.7 Hz, 1H), 1.40 (d, J= 6.6 Hz. 6H).
Example 32 Préparation of l-(2-formyl-3-hydroxyphenethyl)piperidine-4-carboxylic acid (Compound 55).
To a solution of 2-bromo-6-hydroxybenzaldehyde (3.8 g, 18.91 mmol, 1 eq.) in a mixture of THF and MeOH (4/1, 25 mL) was added NaBH4 (1.4 g, 37.81 mmol, 1.5 eq.) at rt portionwise. Upon the completion of addition, the mixture was continued to stir at rt for 30 min.
The mixture was quenched with HCl (4 N) and extracted with EtOAC twice. The combined organic layer was dried over Na2SO4, concentrated , and purified on silica gel using 25% ·
EtOAc/hexanes as eluent to give 3-bromo-2-(hydroxymethyl)phenol (2.3 g, 60%) as a colorless oil.
To 3-bromo-2-(hydroxymethyl)phenol (2.3 g, 11.3 mmol, 1 eq.) in acetone (20.0 mL) were added 2.2-dimethoxypropane (6.0 mL), PTSA (215 mg. 1.13 mmol, 0.1 eq.), and Na2SO4 (5.0 g). The mixture was heated at 40 °C O/N, cooled to rt, and diluted with EtOAc. The organic layer was washed with NaHCO3(Sat.j solution and brine, dried over Na2SO4, concentrated, and purified on silica gel using a mixture of EtOAc and hexanes to give 5-bromo-2,2-dimethyl4H-benzo[d][l,3]dioxine (2.1 g, 76%) as a colorless oi. ’H NMR (4OO.MHz, CDCI3) δ 7.13 (dd, J =8.0, 1.2 Hz. 1H). 7.07 (t,J=8.0 Hz, 1H), 6.81 (dd,J=8.0,1.2 Hz, 1H), 4.77 (s, 2H), 1.56 (s, 6H).
To a mixture of 5-bromo-2,2-dimethyl-4H-benzo[d][l,3]dioxine (2.1 g, 8.64 mmol, 1 eq.), Pd2(dba)3 (400 mg, 0.43 mmol, 0.05 eq.), Q-Phos (460 mg. 0.65 mmol, 0.075 mmol) in THF (100 mL) purged with N2 for 10 min was added /00(0112002¾¾ (0.5 M/ether, 35mL.
17.38 mmol, 2 eq.). The mixture was heated at 50 °C for 16 h, cooled to rt, added NH4Cl(sat) solution, and diluted with EtOAc. The organic layer was separated, dried over Na2SO4, concentrated, and purified on silica gel using a mixture of EtOAc and hexanes to give tertbutyl 2-(2,2-dimethyl-4H-benzo[d][l,3]dioxin-5-yl)acetate (2.6 g, 80% pure. 87%) as a brownoil. 'HNMR (400 MHz, CDCI3) δ 7.06 (t,J=7.9 Hz, 1H), 6.73 (d,J=7.4 Hz, 1H), 6.68 (d, J = 8.2 Hz, 1 H), 4.78 (s, 2H). 1.47 (s, 6H), 1.36 (s, 9H).
To a solution of tert-butyl 2-(2,2-dimethyl-4H-benzo[d][l,3]dioxin-5-yl)acetate (2.6 g, 80% pure, 9.34 mmol, 1 eq.) in THF (20 mL) were added LiBH4 (7.0 mL, 14.01 mmol, 1.5 eq.) and MeOH (1.0 mL) at rt. The mixture was stirred at rt for 30 min, added MeOFI (20 mL), concentrated to dryness, added MeOH (20 mL) and silica gel, and concentrated to dryness again. The mixture was loaded directly on silica gel for purification using a mixture of EtOAc and hexanes as eluent to give 2-(2,2-dimethyl-4H-benzo[d][l,3]dioxin-5-yl)ethanol (1.1 g, 71%) as a pale brown oil. 'H NMR (400 MHz, CDC13) δ 7.28 (t, J= 7.9 Hz, 1H), 6.92 (d, J= 7.4 Hz, 1H), 6.86 (d, J= 8.2 Hz, 1H), 5.02 (s, 2H), 3.99 (q, J= 6.4 Hz, 2H), 2.86 (t, J = 6.6 Hz, 2H), 1.68 (s, 6H), 1.57 (t, J =5.5 Hz, 1H).
To a solution of 2-(2,2-dimethyl-4H-benzo[d][l,3]dioxin-5-yl)ethanol (400 mg. 1.92 mmol, 1 eq.) in THF (20 mL) were added MsCl (438 mg, 3.84 mmol, 2.0 eq.) and TEA (0.8 mL, 5.76 mmol, 3.0 eq.) at rt. The mixture was stirred at rt for 1 h and diluted with EtOAc. The organic layer was washed with water and brine, dried over Na2SO4, and concentrated to give 2-(2,2-dimethyl-4H-benzo[d][l,3]dioxin-5-yl)ethyl methanesulfonate (400 mg, crude) as a pale brown oil, which was used for next step withoui purification.
To 2-(2,2-dimethyl-4H-benzo[d][l,3]dioxin-5-yl)ethyl methanesulfonate (176 mg, 0.59 mmol, crude above, 1 eq.) in DMF (1.0 mL) was added ethyl piperidine-4-carboxylate (186 mg, 1.18 mmol, 2.0 eq.) at rt. The mixture was stirred at 60 °C for 2 h, cooled to rt, and purified on RP-HPLC (Gemini 21.2 mm x 150 mm) using a mixture of CFI3CN and water (0.1% HCOOH) as eluent to give ethyl 1 -(2-(2,2-dimethyl-4H-benzo[d][l,3]dioxin-5yl)ethyl)piperidine-4-carboxylate (100 mg, 49% for two steps). JH NMR (400 MHz, CDCI3) δ 8.45 (s, 1 H), 7.13 (t, J = 7.9 Hz, 1 H), 6.73 (d, J = 7.9 Hz, 2H), 4.86 (s, 2H), 4.19 (q, J = 7.1 Hz, 2H), 3.22 (s, 2H), 3.09 - 2.95 (m, 1H), 2.95 - 2.79 (m. 4H), 2.76 (s, 1H), 2.66 - 2.48 (m, 1H), 2.23 - 1.99 (m, 4H), 1.55 (s, 6H), 1.29 (t, J= 7.1 Hz. 3H). LRMS (M+H+) m/z 348.1.
To ethyl 1 -(2-(2,2-dimethyl-4H-benzo[d][l ,3]dioxin-5-yÎ)ethyl)piperidine-4-carboxylate ( 100 mg, 0.49 mmol, 1 eq.) in THF (10 mL) were added HCl (6 N, 10 drops) and water (1.0 mL) at rt. The mixture was stirred at 60 °C for 2 h, cooled, and basified with NaHCO3(Sat.) solution. The mixture was filtered and concentrated. The residue was bring into THF (10 mL) and filtered. The filtrate was concentrated to give ethyl l-(3-hydroxy-2(hydroxymethyl)phenethyl)piperidine-4-carboxylate (85 mg, crude) as a pale brown oil, which was used for next step without purification. LRMS (M+H+) m/z 308.1.
To ethyl l-(3-hydroxy-2-(hydroxymethyl)phenethyl)piperidine-4-carboxylate (85 mg, crude above) in THF (20.0 mL) was added MnO2 (500 mg, 5.75 mmol ) at rt. The mixture was stirred at rt for 1 h, filtered, and concentrated to give ethyl l-(2-formyl-3hydroxyphenethyl)piperidine-4-carboxylate (80 mg, crude) as a pale brown solid, which was used for next step with purification. LRMS (M+H+) m/z 306.1.
To ethyl l-(2-formyl-3-hydroxyphenethyl)piperidine-4-carboxylate (80 mg, crude above) m THF (5.0 mL) was added NaOFI (3 N, 1.0 mL). The mixture was stirred at rt for 2 h and acidified to pH 3-4 using HCl (2 N). The mixture was concentrated and purified on RPHPLC (Gemini 21.2 mm x 150 mm) using a mixture of CH3CN and water (0.1% HCOOH) as eluent to give l-(2-formyl-3-hydroxyphenethyl)piperidine-4-carboxylic acid (40 mg, 29% for three steps) as a yellow solid. Ή NMR (400 MHz, DMSO) δ 10.26 (s, 1H), 8.65 (s. 2H), 6.91 (dd,J=8.7, 6.9 Hz, 1H), 6.16 (d,J= 7.9 Hz, 1H), 5.76 (d, J=6.7Hz, 1H), 3.01 -2.89 (m, 4H), 2.50 - 2.36 (m, 2H), 2.03 (t, J = 10.3 Hz, 2H), 1.92 - 1.76 (m, 3H), 1.69 - 1.49 (m, 2H). LRMS (Μ+Η*) m/z 278.4. 'H NMR (400 MHz, DMSO-d6) δ 10.1 (s, 1H), 8.55 (s, 2H), 6.75(dd, J = Hz, 1H), 6.05 (d, J = Hz, 1H), 5.6 (d, J = Hz, 1H), 2.7 (m, 4H), 2.3 (m, 2H),L85 (m, 2H),L7 (m, 3H),1.5 (m, 2H).
IN VITRO TESTING
Example 33. Modulation of Hemoglobin Oxygen affinity by Substituted Benzaldehyde Compounds—Assay Procedure.
Oxygen equilibrium curves (OEC) in purified Hemoglobin S (HbS) were measured by the change in p50, the partial pressure of oxygen at which the heme binding sites in the HbS sample are 50% saturated with oxygen. HbS was purified by a modified procedure (Antonini and Brunori, 1971; Heomoglobin and Myoglobin in their Reactions with Ligands; North Holland Publishing Company; Amsterdam, London) from blood obtained from homozygous sickle cell patients though the Hemoglobinopathy Center at Children's Hospital Oakland Research Institute (CHORI) with Institutional Review Board approval. Oxygen equilibrium curves were carried out with a HEMOX analyzer, (TCS Scientific, New Hope, PA). Five hundred pL of 250 μΜ purified HbS were diluted into 4.5 mL of HEMOX buffer (30 mM TES, 130 mM NaCl, 5 mM KC1, pH= 7.4) resulting in a final hemoglobin concentration of 25 μΜ. The compounds were added at the final desired concentrations. The mixture was incubated for 45 min at 37 °C and then transferred to the Hemox sample chamber. The samples were saturated with oxygen by flushing with compressed air for 10 minutes. The samples were then flushed with pure nitrogen and the absorbance of deoxy-Hb was recorded as a function of the solution pû2. The oxygen equilibrium data was then fit to the Hill Model to obtain values for p50. The deoxygenation curves for both HbS alone (control) and HbS in the presence of compound were collected with the TCS software. The p50 for purified Hbs was typically 13.8 + 1.6. Delta p50 values were obtained from the p50 value for control
.............' 19779 minus the p50 value for HbS treated with compound divided by the p50 value for the control. A positive delta p50 value corresponds to a left shifted curve and a lower p50 value relative to control, indicating that the compound acts to modulate HbS to increase its affinity for oxygen.
Example 34. Modulation of Hemoglobin Oxygen affinity by Substituted Benzaldehyde Compounds—Assay Results.
The compounds of Table 1 that were where tested in the assay above were ail found to hâve positive delta p50 values. Delta p50% is calculated from [[p50(HbS) - p50(HbS treated with compound)]/p50(HbS)] X 100. Table 2 below lists the delta p50% values where + indicates a 10 delta p50% of between 0 and 29 and ++ indicates a delta p50% of 30 or greater. Unless noted otherwise, the compounds in Table 2 were tested at 30μΜ.
Table. delta p50
Compound | delta p50 |
1 | -H- |
2 | + |
3 | + (100μΜ) ’ |
4 | + |
5 | |
6 | + (100μΜ) |
7 | -H- |
8 | + |
9 | + |
10 . | ++ |
11 | + |
12 | + (100μΜ) |
13 | + |
14 | + |
15 | + (100μΜ) |
16 | + |
21 | + (100μΜ) |
23 | ++ |
24 | -H- |
25 | -H- |
+ (100μΜ) | |
34 | + |
35 | + |
37 | + |
38 | ++(100μΜ) |
39 | + (100μΜ) |
40 | + |
41 | |
42 | |
43 . | |
44 | |
45 |
Example 35. Polymerization Assay.
Polymerization assays are carried out in vitro using purified HBS exchanged into 1.8 M potassium phosphate buffer at pH 7.4. Using a slightly modified protocol (Antonini and
Brunori, 1971), HbS is purified by the CRÛ VIRUSYS, from blood obtained from homozygous sickle cell patients through the Hemoglobinopathy Center at Children's Hospital Oakland Research Institute (CHORI) with Institutional Review Board approval. Compounds are prepared in 100% DMSO and a desired amount is added to 50 μΜ of purified HBS at a final DMSO concentration of 0.3%. Final potassium phosphate concentration is adjusted to
1.8 M using a combination of 2.5 M potassium phosphate stock solution and water at pH 7.4.
The reaction mixture is incubated for an hour at 37 °C and then transferred into a 24-well plate for deoxygenation in a glove box containing 99.5 % nitrogen and 0.5% oxygen. The ~--... 19779
24-well plate is not covered and incubated at 4 °C on a plate cooler inside the glove box for one and a half hours. Fifty pL of the reaction mixture is transferred into a 96-well plate and the absorbance at 700 nm is measured every minute for one hour at 37 °C in a plate reader located inside the glove box. A plot of the absorbance against time is fitted using a Bohzman 5 sigmoidal fit and the delay time (from zéro to time at half Vmax) is measured. To compare and rank compounds, delay times are expressed as percent delay (%DT), which is defined as the différence in delay times for HBS/compound and HBS alone multiplied by 100 and divided by the delay time for HBS alone.
Compounds listed below hâve been tested in the polymerization assay. Activity ranges are 10 defined by the number of dagger (t) symbols indicated. t dénotés activity > 40% but < 80%; .
ff dénotés activity > 80% but < 120%; ttt dénotés activity > 120% but < 140%; ttT'f dénotés activity > 160%. ;
Compound | % delta Delay |
42 | tt |
43 | tt |
44 | t |
45 | tt |
46 | t |
47 | TT |
48 | t |
49 | 1 |
Example 36. R/T Assay
A relaxed-to-tense transition assay (“R/T assay”) was used to détermine the ability of substituted benzaldehyde compounds to mantain the high-oxygen affinity relaxed (R) State of hemoglobin under deoxygenated conditions. This ability can be expressed as a “delta R” value (i.e.. the change in the time-period of the R State after hemoglobin is treated with a compound, as compared to the period without treatment with the comound). Delta R is the %R to remaining after the compounds treatment compared with no treatment (e.g. if R%
.....19779 without treatment is 8% while with treatment with a target compound is 48% R at 30 μΜ, then %R is 40% for that compound.
«
A mixture of HbS/A was purified from blood obtained from homozygous sickle cell patients though the Hemoglobinopathy Center at Children's Hospital Oakland Research Insiitute (CHORI) with Institutional Review Board approval. HbS/A (at a final concentration of 3 μΜ) was incubated for 1 hr at 37°C in presence or absence of compounds in 50 μΜ potassium phosphate buffer, pH=7.4 and 30 μΜ 2, 3 diphosphoglycerate (DPG) in 96 well plates in a final volume of 160 μΐ. Compounds were added at different concentrations (3 μΜ to 100 μΜ final concentrations). Plates were covered with a Mylar film. After incubation ’ 10 was completed the Mylar cover was removed and the plates were placed in a Spectrostar
Nano plate reader previously heated at 37°C. Five minutes later, N2 (flow rate = 20 L/min) was flowed through the spectrophotometer. Spectroscopic measurements (300 nm to 700 nm) were taken every 5 min for 2 hours. Data analysis was performed by using linear régression from the data retrieved for ail wavelengths.
Table 4 below lists the delta R values where + indicates a delta R of between 0 and 30, ++ indicates a delta R of between 30 and 50, and +++ indicates a delta R of 50 or greater. Unless noted otherwise, the compounds in Table 2 were tested at 9 μΜ.
Table. delta R
Compound | delta R (%) |
5 | Ή- |
10 | -H- |
24 | + |
25 | |
41 | -L |
42 | +Ή- |
(30 pm) | |
43 | (30 pm) |
44 | | | | |
45 | -r-H- |
Example 37. Whole Blood Assay
Oxygen Equilibrium Curves (OEC) of whole blood before and after treatment with different concentrations of substituted benzaldehyde compounds were performed as follows using a HEMOX analyzer (TCS Scientific, New Hope, PA). Blood samples from homozygous sickle cell patients were obtained though the Hemoglobinopathy Center at Children's Hospital Oakland Research Institute (CHORI) with Institutional Review Board approval. The hematocrit was adjusted to 20% using autologous plasma and the blood samples were incubated for 1 hour at 37 °C in absence or presence of compounds. 100 μΐ of these samples were added to 5 mL of Hemox buffer (30 mM TES, 130 mM NaCl, 5 mM KC1, pH= 7.4) at 37 °C and then transferred to the Hemox sample chamber. The samples were saturated with oxygen by flushing with compressed air for 10 minutes. The samples were then flushed with pure nitrogen and the respective absorbances of oxy- and deoxy-Hb are recorded as a function of the solution pO2. The oxygen equilibrium data were then fitted to the Hill Model to obtain values for p50. The deoxygenation curves for both whole blood alone (control) and whole blood in the presence of the compound were collected with the TCS software.
Table 5 below lists the delta p50% values where + indicates a delta p50% of between 0 and 29, ++ indicates a delta p50% of between 30 and 50, and +++ indicates a delta p50% of 50 or greater. The compounds in Table 2 were tested at 1000 pM. A positive delta p50 value corresponds to a left shifted curve and a lower p50 value relative to control, indicating that the compound acts to modulate HbS to increase its affinity for oxygen.
Table . delta p50% Values for Whole Blood Assay
Compound | delta p50% |
42 | + |
43 | +++ |
44 | + |
45 | -L |
Example 38. Pharmacokinetic Study of Compound 43 (HCl sait)
I. V. STUDY
Sprague Dawley rats were treated with 7.8 mg/Kg of Compound 43 dissolved in
10%DMA:50%PEG:16%ca vitron. At specified time pojnts 10 uL of whole blood/plasma was removed from rats and treated with490ul pH 3 buffer + 500 uL ACN/IS, then shaken for 1 hour, centrifuged for 10 minutes at 57 rpm at 4C. The supematant was transferred to a fdter plate and centriguged at 2000 rpm for 1 minute at 4C. The samples were then analyzed by LC-MS/MS monitoring parent aldéhyde. Concentrations in blood and plasma are shown in Table 5. Key P/K parameters are shown in Table 6.
Table
Compound 43 7.8mpk IV in rat | ||||||
blood conc (uM) | plasma conc (uM) | |||||
time (min) | A | B | C | A | B | C |
0 | BLLOQ | BLLOQ | BLLOQ | BLLOQ | BLLOQ | BLLOQ |
5 | 259 | 246 | 281 | 7.56 | 8.68 | 7.44 |
15 | 287 | 341 | 285 | 8.38 | 8.42 | 7.16 |
30 | 283 | 333 | 292 | no sample | 8.66 | 7.1 |
60 | 256 | 203 | 285 | 6.12 | 7.52 | 7.22 |
120 | 263 | 274 | 280 | 3.92 | 6.02 | 5.22 |
240 | 248 | 225 | 259 | 3.72 | 5.24 | 5.88 |
480 | 118 | 136 | 22.9 | 2.06 | 2.66 | 3.15 |
1440 | 81.1 | 85 | 70.8 | 1.07 | 1.38 | 1.51 |
Table
Compound 43 7.8mpk IV in rat | |||
Blood | Plasma | ||
tl/2 beta | min | 749.0 | 619.1 |
CL | ml/min/kg | 0.08 | 4.45 |
Vss | L/kg | 0.09 | 4.11 |
AUClast | min*umol/L | 215846.3 | 4114.8 |
ORALSTUDY
SD Rats were treated by gavage with 44 mg/kg and 100 mg/kg dissolved in 10%DMA:90%
PEG. At specified time points blood was taken and worked up as described above in the IV Study. Key Parameters are shown in Table 7.
Table
Compound 43 :2 PO in rats | |||||||
Blood | Plasma | ||||||
ratio | ratio | ||||||
dose | mg/kg | 44 | 100 | 2.27 | 44 | 100 | 2.27 |
Tmax | min | 320.00 | 720.00 | 200.00 | 680.00 | ||
Cmax | umol/L | 381.33 | 1096.67 | 2.88 | 14.79 | 44.53 | 3.01 |
AUClast | min*umol/L | 395638.27 | 1384101.11 | 3.50 | 12517.54 | 52836.17 | 4.22 |
Ail patents, patent applications, publications and présentations referred to herein are incorporated by reference in their entirety. Any conflict between any reference cited herein and the teaching of this spécification is to be resolved in favor of the latter. Similarly, any conflict between an art-recognized définition of a word or phrase and a définition of the word or phrase as provided in this spécification is to be resolved in favor of the latter.
Claims (2)
- Ciaims:1. A compound having the structure:namely, 2-hydroxy-6-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde.
- 2. A pharmaceutical composition comprising:namely, 2-hydroxy-6-((2-( 1 -isopropyl-1 H-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde, and at least a pharmaceutically acceptable excipient.Use of a compound having the structure:namely, 2-hydroxy-6-((2-(l -isopropyl-1 H-pyrazol-5-yl)pyridin-3yl)methoxy)benzaldehyde, and at least a pharmaceutically acceptable excipient, in the manufacture of a médicament for treating sickle cell disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61/581,053 | 2011-12-28 | ||
US61/661,320 | 2012-06-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA19779A true OA19779A (en) | 2021-04-30 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017232206B2 (en) | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation | |
US20170107199A1 (en) | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation | |
OA19779A (en) | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation. | |
OA17169A (en) | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation. |